bims-carter Biomed News
on CAR-T Therapies
Issue of 2026–11–08
sixty-one papers selected by
Luca Bolliger, lxBio



  1. Front Immunol. 2026 ;17 1896088
      Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment landscape of hematological malignancies; however, its broader clinical implementation remains constrained by the complexity, cost, and variability of current manufacturing workflows. Conventional CAR T-cell production relies on multistep ex vivo processes including T-cell activation, genetic engineering, expansion, and quality control, each of which influences the phenotype, persistence, and therapeutic efficacy of the final cellular product. Increasing evidence indicates that manufacturing is not merely a logistical process, but a critical biological determinant of CAR T-cell function. Consequently, the field is undergoing a conceptual transition from maximizing expansion and transduction toward actively engineering therapeutically favorable cellular states. Recent advances in nanotechnology and biomaterials engineering provide unprecedented opportunities to address these challenges through precise control of biochemical, spatial, and mechanical cues governing T-cell behavior. This review discusses emerging nanotechnology-enabled strategies across the complete CAR T-cell manufacturing pipeline. The review examines engineered activation platforms that exploit substrate stiffness, topography, ligand organization, and mechanobiological signaling to tune T-cell activation, differentiation, and exhaustion. It further discusses nanotechnology-based approaches for improving viral transduction and enabling non-viral CAR delivery through lipid nanoparticles, nanostructured interfaces, and intracellular delivery systems. Emerging strategies for engineering expansion microenvironments designed to preserve stem-like and memory phenotypes, as well as in vivo CAR generation strategies that may bypass conventional ex vivo manufacturing altogether, are then highlighted. Finally, we highlight nanoscale biosensing and analytical platforms that enable real-time manufacturing monitoring, quality control and adaptive process optimization. Collectively, these advances position nanotechnology as a transformative platform for next-generation CAR T-cell manufacturing.
    Keywords:  CAR T cells; cancer; immunotherapy; nanomaterials; nanotechnology
    DOI:  https://doi.org/10.3389/fimmu.2026.1896088
  2. Crit Rev Oncol Hematol. 2026 Nov 06. pii: S1040-8428(26)00576-7. [Epub ahead of print] 105689
      In recent years, chimeric antigen receptor T-cell (CAR-T) therapy has emerged as an effective treatment for haematological malignancies, including lymphoma and leukaemia. However, its clinical application is associated with several challenges, including severe toxicities such as cytokine release syndrome and neurotoxicity, high manufacturing costs, prolonged production times, and delays associated with patient-specific manufacturing. These limitations have prompted the development of safer, more accessible immunotherapeutic alternatives. Chimeric antigen receptor natural killer (CAR-NK) cell therapy has emerged as a promising next-generation approach that may offer comparable antitumour activity with a potentially more favourable safety profile than CAR-T therapy. CAR-NK cells generally have a lower risk of severe cytokine release syndrome and neurotoxicity, as well as a substantially lower risk of graft-versus-host disease. Moreover, CAR-NK cells can be generated from allogeneic donor sources, supporting the development of off-the-shelf products that may reduce manufacturing time and costs. By combining antigen-specific tumour recognition with the innate cytotoxic mechanisms of natural killer cells, CAR-NK therapy may enhance tumour cell killing. Recent preclinical and clinical studies in haematological malignancies and solid tumours have reported promising antitumour activity and encouraging safety outcomes. Overall, CAR-NK therapy represents a promising complementary approach to CAR-T therapy, with potential advantages in safety and off-the-shelf manufacturing. However, CAR-T therapy has a more established clinical evidence base, particularly in haematological malignancies, and can achieve substantial in vivo expansion and durable remissions. The relative benefits of these platforms depend on the disease context, treatment objectives, and clinical evidence available for each product. Further comparative studies are needed to define their respective roles in cancer immunotherapy.
    Keywords:  CAR-NK cell therapy; CAR-T therapy; Cancer immunotherapy; adoptive cell therapy; cellular engineering; cytokine release syndrome; graft-versus-host disease; haematological malignancies; off-the-shelf therapy; solid tumors; targeted therapy
    DOI:  https://doi.org/10.1016/j.critrevonc.2026.105689
  3. Cancer Chemother Pharmacol. 2026 Nov 05. pii: 127. [Epub ahead of print]96(1):
      Chimeric antigen receptor T cell (CAR-T) therapy has emerged as a prominent cancer treatment modality, demonstrating significant clinical success. To date, several CAR-T products have been approved by the U.S. Food and Drug Administration (FDA) for the management of hematological malignancies. Despite these advances, several challenges continue to limit the broader application of CAR-T therapy. These challenges include complex and costly manufacturing processes, safety concerns associated with integrating viral vectors, individualized production requirements, therapy-related adverse effects, and limited efficacy against solid tumors. Recent progress in ribonucleic acid (RNA)-based technologies has introduced promising strategies to improve the safety, adaptability, and therapeutic performance of CAR-T cells. This review provides a comprehensive translational perspective on the integration of RNA technologies with CAR-T therapy. Specifically, it categorizes current approaches into four key areas: RNA-driven non-viral CAR-T cell manufacturing, RNA vaccine-mediated enhancement of CAR-T activity, RNA interference (RNAi)-based modulation, and in vivo CAR-T cell generation. Among the reviewed approaches, ex vivo messenger RNA (mRNA)-based CAR-T engineering currently has the greatest clinical maturity, whereas RNA vaccine-mediated boosting shows particular promise for enhancing CAR-T expansion and persistence, especially in solid tumors. In vivo RNA-mediated CAR-T generation remains at an early stage of development, with evidence still predominantly derived from preclinical studies, but may ultimately represent the most transformative approach by simplifying manufacturing and improving accessibility.Trial registration number: Not applicable.
    Keywords:  CAR-T; Non-viral gene delivery; RNA interference; RNA-based technologies; mRNA engineering
    DOI:  https://doi.org/10.1007/s00280-026-04961-2
  4. Cancer Treat Res Commun. 2026 Oct 29. pii: S2468-2942(26)00421-1. [Epub ahead of print]49 101512
      Skin cancers comprise a biologically diverse group of malignancies with distinct molecular alterations, immune landscapes, and mechanisms of therapeutic resistance. Although immune checkpoint inhibitors have improved outcomes, particularly in melanoma and Merkel cell carcinoma, primary and acquired resistance remain common, underscoring the need for complementary immune-based strategies. Chimeric antigen receptor (CAR)-engineered cellular therapies redirect immune cells toward selected tumor-associated antigens. Despite the clinical success of CAR-T cells in hematological malignancies, their application to solid skin cancers remains challenging because of antigen heterogeneity, immunosuppressive tumor microenvironments, limited infiltration, and inadequate persistence. CAR engineering has expanded beyond conventional T cells, but clinical maturity varies: CAR-T therapy is established in hematological malignancies, whereas CAR-natural killer (CAR-NK) cells and CAR-macrophages (CAR-M) have entered early clinical investigation in selected cancers. CAR-dendritic cells (CAR-DC), CAR-B cells, CAR-natural killer T (CAR-NKT) cells, and CAR-γδ T cells remain predominantly preclinical or conceptual for skin cancers. Their proposed functions include cytotoxicity, innate recognition, phagocytosis, and antigen presentation, but clinical efficacy in cutaneous malignancies has not been established. This narrative review synthesizes target biology, evidence maturity, therapeutic limitations, and emerging engineering strategies. We also propose a hypothesis-generating framework for studying CAR-platform selection according to tumor subtype, antigen characteristics, immune contexture, and mechanisms of immune escape.
    Keywords:  Chimeric antigen receptor (CAR) therapy; Melanoma, CAR-NK cells; Skin cancer immunotherapy; Tumor microenvironment
    DOI:  https://doi.org/10.1016/j.ctarc.2026.101512
  5. Int J Hematol. 2026 Nov 06.
      Chimeric antigen receptor T-cell (CAR-T) therapy, originally developed for B-cell malignancies, is rapidly being repurposed for severe systemic autoimmune rheumatic diseases. The rationale extends beyond suppression of autoantibody production, as B cells also function as antigen-presenting cells, cytokine producers, and organizers of pathogenic immune interactions. CD19-directed CAR-T cells can achieve broader and deeper B-cell depletion than conventional antibody-based approaches and may disrupt self-sustaining autoimmune networks. Early clinical experience across systemic autoimmune diseases has shown striking responses, including drug-free remission in selected patients. Importantly, disease control may persist despite CAR-T contraction and subsequent B-cell reconstitution, supporting the concept of an "immune reset," although this should not be equated with cure. In autoimmune diseases, long-term CAR persistence may not be required, and toxicity profiles and therapeutic goals differ from those in hematologic malignancies. Meanwhile, clinical development is expanding beyond autologous CD19-directed CAR-T cells to BCMA-directed, dual-target, allogeneic, natural killer cell, induced pluripotent stem cell-derived, and in vivo CAR platforms. This review discusses the biological rationale, emerging clinical evidence, safety and management considerations, and future development of CAR-based cellular therapy for systemic autoimmune rheumatic diseases.
    Keywords:  B-cell depletion; CAR-T therapy; CD19; Immune reset; Systemic autoimmune rheumatic disease
    DOI:  https://doi.org/10.1007/s12185-026-04306-y
  6. Immunotherapy. 2026 Nov 06. 1-15
      Nanobody-based chimeric antigen receptors (CARs) represent a promising strategy for improving the specificity, modularity, and clinical adaptability of cellular immunotherapies. Replacing conventional single-chain variable fragments with camelid-derived variable heavy-chain domains (VHHs) may enhance receptor stability, antigen accessibility, and construct design. This review summarizes nanobody-based CAR applications across T cells, natural killer (NK) cells, γδ T cells, and macrophages, drawing on literature published between 2011 and 2026 and identified through PubMed/MEDLINE, Scopus, Web of Science, and Google Scholar. Nanobody-based CAR-T cells support recognition of hematologic and solid tumors and facilitate dual targeting, tandem receptors, affinity tuning, and immune-modulating designs. CAR-NK cells combine antigen-directed activity with innate cytotoxicity and potential advantages for allogeneic, off-the-shelf treatment. CAR-γδ T cells integrate innate-like surveillance with engineered specificity and may offer reduced graft-versus-host disease risk. CAR-macrophages exploit phagocytosis and tumor microenvironment remodeling to promote antitumor responses. Emerging universal, switchable, -generated, and synthetic antigen-based CAR platforms further highlight the versatility of nanobodies for controllable and scalable therapies. Collectively, these approaches offer opportunities to address tumor heterogeneity, antigen escape, and treatment safety, although further preclinical optimization and rigorous clinical evaluation are needed to establish their efficacy, persistence, and long-term safety in diverse patient populations and clinical settings.
    Keywords:  Immunotherapy; adoptive cell transfer; chimeric antigen; nanobodies; natural killer cells; receptors; tumor microenvironment
    DOI:  https://doi.org/10.1080/1750743X.2026.2755254
  7. Clin Transl Sci. 2026 Nov;pii: e70756. [Epub ahead of print]19(11):
      CAR-T therapy has improved outcomes in selected relapsed or refractory hematologic malignancies. However, rational dose-relevant decision application remains challenging because the administered (nominal) cell dose does not reliably predict in vivo exposure, toxicity, or clinical response. These relationships are not adequately characterized by empirical dose escalation alone. Mechanistic modeling may offer a biologically interpretable way to connect preclinical evidence and patient-level CAR-T posology, but its application remains incompletely defined. We conducted a systematic scoping review using JBI methodology and PRISMA-ScR guidance, searching MEDLINE, Embase, Scopus, and Google Scholar (2010-2025). Eligible studies reported original CK/PD, PK/PD, QSP, PBPK/PD, stochastic, or agent-based models for dose-relevant application or regimen optimization. Nineteen studies met the inclusion criteria (13 mechanistic and 6 semi-mechanistic models) spanning hematologic and solid-tumor settings. Although these studies evaluated aspects of CAR-T pharmacology, none provided prospectively validated clinical dose-selection evidence. Overall, CAR-T expansion appeared to be more influenced by tumor burden, antigen engagement, product-specific attributes, lymphodepletion, and host or tumor-site factors than by nominal dose. Solid-tumor models highlighted delivery route, trafficking, biodistribution, and microenvironment barriers. Emerging in vivo CAR-T platforms shifted dose considerations toward vector or mRNA dose and repeat dosing. Mechanistic modeling appears useful for framing CAR-T dose-relevant and regimen questions, but the current evidence is best interpreted as a taxonomy of model applications rather than proof of prospective clinical dose selection utility. Consistent with ICH M15 principles, future clinical, and regulatory application will require defined context of use, stronger validation, uncertainty assessment, and biological integration.
    Keywords:  cancers; dose; mathematical modeling; mechanism‐based pharmacokinetics‐pharmacodynamics; model‐based drug development; multiscale modeling; quantitative pharmacology; translational medicine; translational pharmacokinetics‐pharmacodynamics
    DOI:  https://doi.org/10.1111/cts.70756
  8. Int Immunol. 2026 Nov 03. pii: dxag056. [Epub ahead of print]
      Adoptive cell therapy has emerged as a powerful approach for treating hematologic malignancies. Among these strategies, chimeric antigen receptor (CAR) T cell therapy has demonstrated remarkable clinical efficacy, especially for treating B cell malignancies. Several CAR T cell products have been approved for clinical use. Additionally, CAR-engineered natural killer (CAR NK) cells have recently been developed and have shown promising results in clinical trials for treating B-cell malignancies. However, developing CAR T- or NK-cell therapies for acute myeloid leukemia (AML) has been challenging due to the lack of AML-specific antigens that are not expressed by normal hematopoietic cells. Recently, we developed CAR T- and CAR NK-cell therapies targeting mismatched human leukocyte antigen (HLA)-DRB1 molecules in patients who have undergone allogeneic hematopoietic cell transplantation (allo-HCT). This review summarizes the current status of AML therapy, discusses the challenges of identifying suitable CAR targets, and introduces CAR T- and CAR NK-cell strategies targeting mismatched HLA-DRB1 molecules for treating relapsed AML after allo-HCT.
    Keywords:  Cellular immunotherapy; HLA-DRB1; Hematological cancer
    DOI:  https://doi.org/10.1093/intimm/dxag056
  9. J Microbiol Immunol Infect. 2026 Oct 16. pii: S1684-1182(26)00138-6. [Epub ahead of print]
      Invasive fungal diseases (IFDs) cause substantial global mortality, and current antifungal therapy is limited by resistance, toxicity, and narrow spectrum. Chimeric antigen receptor (CAR)-T cell therapy has achieved success in cancer treatment. Owing to major histocompatibility complex-independent antigen recognition, direct pathogen killing and the ability to enhance host immune responses, CAR-T cells are now being explored for infectious diseases, including IFDs, positioning them as a promising strategy for IFD therapy. Preclinical studies have shown activity against Aspergillus, Candida, Cryptococcus, and other pathogenic fungi. However, no antifungal CAR-T cell product has yet entered clinical trials, and the path to clinical translation remains unclear. Clinical translation faces challenges including manufacturing constraints, the limited number of antifungal CAR-T cell therapies, and safety risks. This review explores the potential and application challenges of CAR-T cells in the treatment of IFD, along with strategies to address these challenges, and proposes a framework for selecting antibody targets based on antigen conservation, surface accessibility, and validation status. It further analyzes the advantages of CAR-T cell therapy for IFD by comparing CAR-T cells with CAR-NK cells. These insights may contribute to the development of antifungal CAR-T cell therapy.
    Keywords:  Allogeneic CAR-T cells; CAR-T cell therapy; Chimeric antigen receptor; Immunotherapy; Invasive fungal diseases
    DOI:  https://doi.org/10.1016/j.jmii.2026.10.008
  10. J Egypt Natl Canc Inst. 2026 Nov 05. pii: 84. [Epub ahead of print]38(1):
      Cancer stem cells (CSCs) are a major contributor to therapeutic resistance, tumour recurrence, and disease progression because of their self-renewal capacity, phenotypic plasticity, immune evasion, and ability to persist after treatment. Chimeric antigen receptor (CAR)-based immunotherapy has transformed the treatment of several hematological malignancies, but effective targeting of CSC-driven disease, especially solid tumour, remains challenging. Antigen heterogeneity and loss, CSC plasticity, CAR-cell dysfunction, metabolic constraints, and an immunosuppressive tumour microenvironment (TME) can limit long-term therapeutic responses. CSC-associated antigens such as CD133, CD44, EpCAM, HER2, CSPG4, ALDH, and EGFRvIII have been investigated as CAR targets, although their heterogeneous and context-dependent expression raises important concerns regarding CSC specificity and on-target/off-tumour toxicity. Artificial intelligence (AI) and computational approaches provide opportunities to integrate genomic, transcriptomic, proteomic, spatial, and clinical data for CSC-associated antigen discovery, biomarker identification, CAR design, patient stratification, and toxicity prediction. However, the evidence supporting these applications varies considerably, ranging from computational and preclinical studies to retrospective clinical modelling, while prospective clinical validation of AI-guided CSC-targeted CAR therapy remains limited. Similarly, next-generation platforms, including CAR-natural killer (CAR-NK) cells, CAR-macrophages (CAR-M), gamma-delta CAR-T cells, and CAR-invariant natural killer T (CAR-iNKT) cells, remain at different stages of translational development. This review critically examines CSC biology, mechanisms of resistance to CAR-based therapy, emerging CAR platforms, and the potential role of AI in precision immunogenetics. Particular emphasis is placed on differentiating CSC-intrinsic, CAR-cell-intrinsic, and TME-mediated resistance and on defining the evidence maturity of AI applications. Finally, current challenges in data availability, tumour heterogeneity, model bias, external validation, interpretability, safety, and prospective clinical translation are discussed, together with priorities for developing clinically validated AI-enabled CSC-targeted CAR therapies.
    Keywords:  Artificial intelligence; CAR immunotherapy; Cancer stem cells; Next-generation CAR therapies; Precision immunogenetics; Therapeutic resistance; Tumour microenvironment
    DOI:  https://doi.org/10.1186/s43046-026-00422-2
  11. Front Immunol. 2026 ;17 1983828
      Solid-tumor CAR T-cell programs increasingly combine biomarker selection, lymphodepletion, manufacturing-state optimization, regional or repeated administration, and engineered control modules. This growing complexity creates a distinct translational problem: the same response, non-response, or toxicity can remain compatible with several competing explanations, obscuring which component actually operated in patient tissue. Mechanism-resolving development addresses this problem by treating each consequential engineering claim as a prospectively testable proposition embedded within the product-trial system. Four questions must be resolved: which patient-relevant state was present, which control action altered it, which proximal tissue transition followed, and which unsafe or limiting state emerged next. Each claim should therefore be paired with a clinically credible lower-burden counterfactual, mechanism-proximal tissue pharmacodynamics, a prespecified falsification criterion, a rescue strategy, and an adaptive action. Boolean coincidence and veto circuits, temporal IF-THEN systems, quantitative antigen-density filters, and genotype-conditioned activator-blocker designs require distinct representations, transition-state assays, and tissue biomarkers. Clinical evidence from CLDN18.2-directed satri-cel, compartmental central nervous system programs, hypoxia-responsive CEA therapy, GPC3-armored products, PSMA programs, and early HLA-loss-gated Tmod therapy illustrates that clinical maturity and mechanistic attribution are not equivalent. Programmability becomes translationally meaningful when the operation of an added control can be distinguished from credible alternatives in patient-relevant tissue, enabling complex cellular engineering to generate falsifiable, cumulative, and clinically actionable knowledge.
    Keywords:  CAR T-cell therapy; adaptive trial design; mechanism attribution; solid tumors; tissue pharmacodynamics
    DOI:  https://doi.org/10.3389/fimmu.2026.1983828
  12. Front Immunol. 2026 ;17 1981337
       Background: Chimeric antigen receptor T (CAR-T) cell therapy has changed the treatment of relapsed or refractory B-cell malignancies and multiple myeloma, but manufacturing time, cost, variability, and access remain major barriers.
    Scope: In this critical narrative review, we position ex vivo T-cell expansion at the interface of biological signaling and engineering design and dissect how each unit operation-from selection and activation to harvest and formulation-influences the final therapeutic product.
    Key advances: Static gas-permeable culture, rocking-motion and stirred-tank bioreactors, hollow-fiber and perfusion systems, biomaterial scaffolds, microcarriers, and defined activation nanoparticles offer distinct routes to scalable expansion. Closed automated platforms now integrate multiple unit operations, while microfluidic systems, rapid manufacturing, and process analytical technologies (PAT) create new possibilities for monitoring and control, with data-driven and AI-assisted prediction emerging as supporting tools rather than established capabilities.
    Challenges: Expansion remains constrained by the trade-off between cell number and preservation of memory phenotype, metabolic fitness, and potency. Donor variability, raw-material quality, consumable dependence, limited interoperability, and incomplete potency assays complicate standardization.
    Outlook: Future progress will depend on coordinated development of defined raw materials, functionally designed consumables, closed-system engineering, interoperable automation, and data-driven process control. The goal is not simply to expand more cells, but to reproducibly manufacture the right cells at an acceptable cost.
    Keywords:  CAR-T cell therapy; automated manufacturing; bioreactor; cell therapy; culture consumables; ex vivo T-cell expansion; single-use system
    DOI:  https://doi.org/10.3389/fimmu.2026.1981337
  13. Clin Exp Med. 2026 Aug 10. pii: 368. [Epub ahead of print]26(1):
      Chimeric antigen receptor (CAR) T cell therapy has shown remarkable efficacy in hematologic malignancies, yet its translation to solid tumors remains a fundamental challenge. Immunologically "cold" tumors, characterized by poor T cell infiltration, dense stromal barriers, and a profoundly immunosuppressive tumor microenvironment (TME), continue to resist conventional CAR-T cell approaches. Armored CAR-T cells engineered to secrete interleukin-18 (IL-18) represent a promising fourth-generation strategy designed to overcome these limitations. IL-18 operates at the interface of innate and adaptive immunity, driving M1 macrophage polarization, dendritic cell maturation, NK cell activation, and the induction of CXCL9/CXCL10 chemokine gradients that restore lymphocyte trafficking into tumor tissue. To guide the rational design of these constructs, bioinformatics pipelines play an increasingly central role. Multi-omics integration of transcriptomic, proteomic, and single-cell RNA sequencing data enables precise tumor antigen selection, epitope prediction, and structural optimization of CAR constructs using tools such as AlphaFold, RosettaDock, and NetMHCpan. In silico safety screening further evaluates off-target toxicity risks and cross-reactivity against healthy tissues. Controlled IL-18 delivery strategies, including NFAT-inducible promoters, SynNotch logic-gated systems, and Granzyme B-cleavable pro-IL-18 constructs, provide spatial and temporal safeguards against systemic hyperinflammation. Preclinical evidence from xenograft and syngeneic models demonstrates enhanced tumor control, sustained T cell persistence, and induction of endogenous anti-tumor immunity. This review synthesizes current evidence and highlights how bioinformatics-guided engineering of IL-18 armored CAR-T cells offers a translatable framework for converting cold tumors into immunologically responsive, therapeutically tractable targets.
    Keywords:  Bioinformatics-guided CAR design; Cold tumor microenvironment; IL-18 armored CAR-T cells; Multi-omics cancer immunology; Solid tumor immunotherapy
    DOI:  https://doi.org/10.1007/s10238-026-02284-3
  14. Med X. 2026 ;4(1): 26
      Cancer immunotherapy has reshaped modern oncology by leveraging immune effector cells to recognize and eliminate malignant tissues. Among cell-based approaches, adoptive cell therapies, most prominently chimeric antigen receptor (CAR) T cells, have produced high response rates and deep remissions in several hematologic malignancies. Despite these clinical successes, broad deployment remains limited by the dominant autologous manufacturing paradigm, which is associated with high per patient cost, prolonged vein to vein time, and heterogeneity in starting material and final product quality, particularly in heavily pretreated patients. Off-the-shelf strategies aim to improve scalability and access by standardizing either the cellular input, such as donor derived or renewable sources, or the engineering reagent used to program immune cells. Here, we review bioengineering approaches enabling three complementary off-the-shelf platforms, including allogeneic CAR T cells, natural killer and invariant natural killer T cell-based therapies, and in vivo CAR generation. Lastly, we outline the clinical translation outlook for off-the-shelf cell therapy, highlighting current limitations and future bioengineering and manufacturing directions. Together, these approaches highlight convergent design principles that will shape the next generation of broadly accessible cell-based cancer immunotherapies, including immune compatibility, controllable activation, and manufacturability.
    Graphical Abstract:
    Keywords:  Bioengineering; Cancer immunotherapy; Cell therapy; In vivo cell engineering; Off-the-shelf immunotherapy
    DOI:  https://doi.org/10.1007/s44258-026-00099-1
  15. Front Immunol. 2026 ;17 1941701
       Background: Chimeric antigen receptor (CAR)-engineered cells are being investigated for urothelial carcinoma, but evidence requirements for antigen selection and local or systemic delivery remain undefined. We asked whether any target or route can presently be prioritised.
    Methods: We combined a systematic evidence map and registry audit with secondary analysis of public bulk and single-nucleus transcriptomes and normal-tissue resources. In GSE169379, infercnvpy used same-object non-epithelial reference cells; epithelial nuclei with high copy-number variation (CNV-high) scores were defined as those above the 99th percentile of reference scores. Aggregate rankings were replaced by two evidence gates: antigen eligibility and then product- and route-specific exposure validation. No new participants or experiments were included.
    Results: All 13 peer-reviewed primary studies were preclinical; none reported a treated patient with urothelial carcinoma. Five registry programmes were retained without bladder-specific results; the only urothelial-specific record changed from recruiting to terminated. Among 21,756 sampled epithelial nuclei from the 29,974-nucleus GSE169379 tumour object, 1,828 were classified CNV-high using 8,218 non-epithelial nuclei from the same object as the reference. Across 18 evaluable patients, median detection fractions were 0.083 for NECTIN4, 0.169 for ERBB2, 0.229 for CD44, 0.267 for EGFR, 0.385 for PSCA and 0.093 for MUC16; corresponding medians in four normal-urothelial batches were 0.290, 0.401, 0.423, 0.598, 0.527 and 0.008. These unpaired cross-object RNA contrasts do not establish a therapeutic window. Equal-dose intravesical MUC16-directed CAR T cells outperformed intravenous administration in two orthotopic xenograft models and showed bladder-localised exposure, but this single programme cannot establish a general route advantage or human safety.
    Conclusions: No evaluated target meets requirements for unqualified clinical prioritisation. Epitope-matched malignant-cell surface expression and functional normal-tissue safety should precede testing whether a specific route achieves the exposure required by the intended disease distribution. Current route evidence is product-specific and preclinical.
    Keywords:  CAR T cell; CAR-NK cell; bladder cancer; chimeric antigen receptor; evidence map; intravesical delivery; single-nucleus RNA sequencing; urothelial carcinoma
    DOI:  https://doi.org/10.3389/fimmu.2026.1941701
  16. Glob Reg Health Technol Assess. 2026 Jan-Dec;13:13 293-300
      Regulation (EU) 2021/2282 on health technology assessment (HTA), hereafter the HTA Regulation (HTAR), entered into application on January 12, 2025, and has introduced a new framework for Joint Clinical Assessments (JCAs) and Joint Scientific Consultations (JSCs) at the European level. In Italy, this transition raises immediate methodological, organizational and relational questions for the Italian Medicines Agency (AIFA), health technology developers (HTDs), scientific societies, patient associations and civic organizations. This Point of View summarizes the perspective developed by Working Group 3 (WG3) during the 8th Edition of the Mogliano Veneto Seminars (25-26 September 2025), dedicated to the implementation of the HTAR in Italy. WG3 identified methodological heterogeneity in early assessment-scope definition, limited formal interaction between national stakeholders, and the absence of an operational national HTA scientific advice as the main practical issues emerging in the first phase of implementation. Five practical recommendations were developed: reactivation of National HTA Scientific Advice; more structured AIFA-HTD interaction in view of national pricing and reimbursement; better alignment between regulatory and HTA pathways from the start of the European Medicines Agency (EMA) procedure through the Member States (MS) scoping input to the assessment scope; capacity building and support for the participation of Italian scientific societies and patient associations in HTAR-related activities; and systematic use of European capacity-building opportunities. The recommendations do not imply legislative reform. Rather, they point to the need for coordinated implementation, clearer interfaces between European and national levels, and better use of existing institutional and scientific capacities.
    Keywords:  AIFA; Early dialog; HTAR; Italy; Joint Clinical Assessment; Joint Scientific Consultation; PICO; Pricing and reimbursement
    DOI:  https://doi.org/10.33393/grhta.2026.3935
  17. Eur J Cancer. 2026 Nov 01. pii: S0959-8049(26)01599-6. [Epub ahead of print]249 117817
       BACKGROUND: Cytokine release syndrome (CRS) may represent a spectrum of treatment-specific phenotypes rather than a uniform clinical entity. To our knowledge, this is the first real-world patient-level comparison of CRS following chimeric antigen receptor T-cell (CAR-T), T-cell engager (TCE), and immune checkpoint inhibitor (ICI) therapy.
    METHODS: CRS cases after CAR-T, TCE (tebentafusp/brenetafusp), or ICI therapy in the SERIO-registry were compared regarding presentation, additional toxicities, management, and tumor outcomes.
    RESULTS: Among 1765 patients registered in SERIO, CRS was documented in 189/213 CAR-T recipients (88.7%), 57/90 TCE recipients (63.3%), and 9/1378 ICI recipients (0.7%). Of those who developed CRS, grade ≥ 3 CRS occurred in 11% of CAR-T and 4% of TCE recipients, but in none of the nine ICI-associated cases. Median onset was 2.5, < 1, and 21.5 days after CAR-T, TCE, and ICI, respectively. Tocilizumab use varied (90%, 4%, and 11%, respectively; CAR-T vs TCE, p < 0.001). Additional treatment-related toxicities affected 43%, 14%, and 56% of CAR-T, TCE, and ICI recipients, respectively (CAR-T vs TCE, p < 0.001; ICI vs TCE, p = 0.034), with distinct patterns: immune effector cell-associated neurotoxicity syndrome (ICANS) predominated after CAR-T, cutaneous toxicities after TCE, and hepatitis or thyroiditis after ICI. CRS resolved in 99-100%; one CRS-related death followed CAR-T. No statistically significant association between CRS occurrence or severity and tumor response was detected.
    CONCLUSION: CRS is not a uniform toxicity, with differences in onset, severity, management, and additional toxicities observed across CAR-T, TCE, and ICI treatment settings. These findings highlight the importance of treatment context in CRS assessment and management.
    Keywords:  CAR T-cell therapy; Cytokine release syndrome; Immune checkpoint inhibitor; Immunotherapy toxicity; Real-world registry; T-cell engager
    DOI:  https://doi.org/10.1016/j.ejca.2026.117817
  18. Int J Hematol. 2026 Nov 02.
      T cell exhaustion is an antigen-driven differentiation program originally defined in chronic infection and now recognized as a major determinant of antitumor immunity. It is best characterized in CD8+ T cells, in which chronic stimulation induces functional impairment, inhibitory-receptor expression, transcriptional and epigenetic reprogramming, and metabolic dysfunction. Exhausted T cells are heterogeneous, ranging from progenitor populations that retain proliferative capacity and responsiveness to programmed cell death protein 1 (PD-1) blockade to terminally exhausted states with limited reversibility. In solid tumors, immune checkpoint blockade acts largely through tumor-reactive exhausted CD8+ T cells. In classic Hodgkin lymphoma, frequent loss of major histocompatibility complex (MHC) class I and retention of MHC class II suggest a greater contribution of cytotoxic CD4+ T cells, and PD-1 blockade may reinvigorate dysfunctional or exhaustion-like CD4+ T cells. Exhaustion also affects chimeric antigen receptor (CAR) T cell and bispecific T cell engager therapies, where repetitive stimulation impairs T cell persistence and function, and allogeneic hematopoietic cell transplantation, where donor T cell exhaustion may influence graft-versus-host disease and graft-versus-leukemia activity. This review summarizes the mechanisms and clinical significance of T cell exhaustion across solid and hematologic malignancies and how exhaustion state shapes therapeutic response.
    Keywords:   T cell exhaustion; Bispecific T cell engagers; CAR T cell; Hematopoietic cell transplantation; Immune checkpoint blockade
    DOI:  https://doi.org/10.1007/s12185-026-04304-0
  19. Exp Mol Pathol. 2026 Nov 05. pii: S0014-4800(26)00077-8. [Epub ahead of print]148 105098
      Cancer immunotherapy has revolutionized oncology by improving therapeutic specificity and efficacy, leading to major clinical successes. Among these approaches, chimeric antigen receptor (CAR-T) cell therapy has shown remarkable results in hematological malignancies. However, its effectiveness in solid tumors is limited by antigen heterogeneity, poor tumor infiltration, and the immunosuppressive tumor microenvironment (TME). To address these limitations, combining CAR-T therapy with oncolytic viruses (OVs) has gained increasing attention. OVs selectively infect and lyse tumor cells while simultaneously stimulating innate and adaptive antitumor immune responses through enhanced antigen release and inflammatory signaling, thereby modulating the TME and enhancing antigen presentation. Evidence from preclinical studies and early clinical trials indicates that CAR-T and OV combination therapy can generate synergistic antitumor effects by improving immune cell infiltration, enhancing cytotoxic activity, and reducing immune evasion. This review highlights recent Advances in the engineering of CAR-T cells and OVs and their synergistic potential in the treatment of solid tumors.
    Keywords:  CAR-T cell; Cancer; Immunotherapy; Oncolytic virus; Tumor microenvironment
    DOI:  https://doi.org/10.1016/j.yexmp.2026.105098
  20. Eur J Haematol. 2026 Nov 04.
       BACKGROUND: mRNA-based vaccines are emerging as a promising platform for cancer immunotherapy, including in hematologic malignancies. Current vaccine development has largely focused on antigen selection, mRNA engineering, lipid nanoparticle (LNP) formulation, and combination with established immunotherapies. However, increasing evidence indicates that the cellular and tissue distribution of antigen expression may critically influence the quality and durability of the immune response. In this context, the term "cellular pharmacology" refers to the principle that the pharmacodynamic effect of an mRNA vaccine is shaped not only by the encoded antigen and formulation but also by the cell types in which antigen expression occurs.
    OBJECTIVES: Here, we propose a cellular pharmacology framework for mRNA vaccines in hematologic malignancies, moving beyond the traditional dendritic-cell-centric model and considering antigen expression as a determinant of immune activation, tolerance, and T-cell exhaustion.
    DISCUSSION: Three functionally distinct compartments can be considered: professional antigen-presenting cells, immunogenic non-immune cells at the injection site, and tolerogenic tissues, particularly hepatocytes. This tripartite model is intended as a simplified functional framework rather than a complete anatomical or cellular classification. While antigen expression in dendritic cells and other antigen-presenting cells supports effective T-cell priming, antigen production by skeletal myocytes and stromal cells may provide a sustained source of antigen for uptake and cross-presentation. Importantly, myocytes should not be regarded as professional antigen-presenting cells, but rather as potential antigen-producing cells whose antigens can be presented by professional APCs. Conversely, hepatic antigen expression may promote peripheral tolerance and impair antitumor CD8+ T-cell responses. Recent preclinical evidence indicates that microRNA-guided hepatocyte detargeting may enhance vaccine-induced immunity and tumor control in experimental models, although its clinical relevance in hematologic malignancies remains to be established. This concept may be particularly relevant in hematologic malignancies, characterized by disseminated disease, chronic antigen exposure, immune dysfunction, and frequent treatment-related organ vulnerability. We discuss how cellular targeting could be incorporated into mRNA vaccine strategies for lymphomas, acute leukemias, chronic lymphocytic leukemia, and multiple myeloma, as well as into combination approaches with CAR-T cells, bispecific antibodies, and immune checkpoint inhibitors.
    CONCLUSIONS: The therapeutic potential of mRNA vaccines in hematologic malignancies may depend not only on the antigen encoded but also on the cellular compartment in which it is expressed. Incorporating tissue biodistribution and cell-type specificity into vaccine design could represent a new strategy to improve immunogenicity while limiting tolerogenic signals and potentially reducing unwanted tissue exposure. At present, however, hepatocyte detargeting should be considered a promising and testable translational strategy rather than a clinically validated approach. Prospective clinical studies integrating biodistribution, immune correlates, and tissue-specific antigen expression will be essential to translate this cellular pharmacology concept into clinical practice.
    Keywords:  T‐cell exhaustion; cancer immunotherapy; cellular pharmacology; hematologic malignancies; hepatocyte detargeting; lipid nanoparticles; mRNA vaccines
    DOI:  https://doi.org/10.1111/ejh.70353
  21. Discov Oncol. 2026 Dec;17 1511
       Objective: This study systematically analyzed the literature on tumor antigen-based cancer immunotherapy by integrating quantitative bibliometric analysis with knowledge network visualization. It aimed to provide an overview of the developmental trajectory of this field, identify major research hotspots and key scientific challenges, and explore the underlying drivers of its evolution, thereby providing references for future antigen-targeted immunotherapy strategies and clinical translation.
    Methods: Literature related to tumor antigen-based cancer immunotherapy was retrieved from the Web of Science Core Collection, covering the period from September 15, 2005, to September 15, 2025. A total of 2,801 research articles were included. Bibliometric data were statistically analyzed using CiteSpace, VOSviewer, Charticulator, Scimago Graphica, and Bibliometrix, and visual scientific network maps were generated.
    Results: Bibliometric analysis showed that annual publication output in this field has remained relatively stable over the past six years, with approximately 170 publications per year and a peak of 188 publications in 2021. Regarding national contributions, the United States ranked first in publication output (1,282 publications), total citations (83,431 citations), and network centrality (0.46). Although China showed rapid growth in publication output and ranked second globally, its overall citation impact remained lower than that of several Western countries. In terms of academic influence, researchers such as Jeffrey Schlom from the National Cancer Institute and Chien-Fu Hung from Johns Hopkins University have maintained important positions through long-term research on tumor antigen recognition, immune regulation, and vaccine development. Temporal keyword analysis revealed an evolutionary transition from early adoptive immunotherapy-related studies, represented by terms such as "transfer therapy" and "adoptive immunotherapy", to immune checkpoint regulatory strategies involving "nivolumab" and "immune checkpoint blockade", and subsequently to emerging tumor antigen vaccine approaches characterized by "nanovaccine" and "mRNA vaccine". Co-citation analysis further supported this evolutionary trajectory, indicating a gradual shift from broadly enhancing immune activation toward precise tumor antigen identification and optimization of antigen-driven immune responses.
    Conclusion: Over the past two decades, tumor antigen-based cancer immunotherapy has evolved from adoptive immune cell therapy and immune checkpoint regulation to personalized neoantigen vaccine strategies, forming a multi-level therapeutic framework involving antigen recognition, immune activation, and targeted delivery. Future advances in antigen prediction, sequencing technologies, mRNA vaccine platforms, and immune regulatory strategies may further promote the development of more precise, effective, and personalized cancer immunotherapies.
    Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1007/s12672-026-05719-1.
    Keywords:  Chimeric antigen receptor; Immune checkpoint inhibitor; Immunotherapy; Tumor microenvironment; Vaccine
    DOI:  https://doi.org/10.1007/s12672-026-05719-1
  22. Clin Rev Allergy Immunol. 2026 Nov 03. pii: 92. [Epub ahead of print]69(1):
      Low-dose interleukin-2 (LD-IL-2) is being developed as an immune-regulatory therapy across rheumatic and autoimmune diseases, but its biology cannot be reduced to regulatory T-cell (Treg) expansion. IL-2 responses are determined by dose and exposure, receptor abundance and binding kinetics, activation state, tissue distribution, and the balance among JAK-STAT5, PI3K-AKT-mTOR, and RAS-MAPK signaling. CD25-high Tregs have a competitive advantage at low concentrations, yet activated conventional T cells, CD8 + T cells, natural killer cells, follicular T-cell subsets, B-cell compartments, and tissue-resident populations may also be modulated directly or indirectly. We therefore synthesize the field through a cross-disease framework linking receptor pharmacology, signaling thresholds, Treg heterogeneity, epigenetic and metabolic fitness, receptor trafficking, and tissue microenvironments to pharmacodynamic, clinical, and durable responses. Disease-specific evidence is critically compared rather than interpreted as a uniform IL-2-deficiency syndrome: systemic lupus erythematosus combines T-cell IL-2 deficiency with Tfh-B-cell and age-associated B-cell pathology; inflammatory arthritis is constrained by synovial cytokine consumption and tissue access; systemic sclerosis by vascular-fibrotic remodeling; inflammatory myopathy by muscle, skin, lung, and microbiome contexts; and neurological autoimmunity by blood-brain-barrier penetration and compartmentalized inflammation. Randomized evidence supports biological activity and preliminary efficacy in selected settings, whereas many indications remain supported by small, uncontrolled studies. Native LD-IL-2 and engineered agonists also require separate evaluation because altered affinity and half-life can change cellular selectivity, immunogenicity, biodistribution, and the risk of chronic receptor overstimulation. We conclude that development should prioritize disease-specific dose-exposure relationships, functional and tissue-resolved biomarkers, rigorous clinical endpoints, and long-term surveillance. This framework positions IL-2 therapy as context-dependent network modulation rather than universal restoration of immune tolerance.
    Keywords:  Autoimmune diseases; Autophagy; Immunometabolism; Low-dose interleukin-2; PI3K-AKT-mTOR; Precision medicine; Receptor trafficking; Regulatory T cells
    DOI:  https://doi.org/10.1007/s12016-026-09214-x
  23. Front Immunol. 2026 ;17 1887951
      Regulatory T cells (Tregs) are essential for immune tolerance and tissue homeostasis. Their dysfunction contributes to a broad range of autoimmune, inflammatory, and degenerative diseases, motivating interest in Treg-based therapies. Clinical translation has been constrained by limited stability, persistence, and functional specialization, particularly within inflammatory tissue environments. Emerging evidence reveals that Tregs are not a uniform suppressive lineage but comprise tissue-adapted populations with distinct transcriptional, metabolic, and functional programs. These cells support organ integrity through mechanisms extending beyond immune regulation, including roles in tissue repair, metabolic tuning, and stem cell niche maintenance that significantly broadens their therapeutic potential. Here, we review established Treg biology and key learnings from select clinical experiences using unmodified Tregs. From there, we discuss the mechanisms and challenges limiting efficacy of Tregs, and present how the state-of-the-art engineering aims to enhance Treg durability, stability, and specificity. Finally, we conclude with a forward-looking perspective on how the future of Tregs can expand beyond immune suppression by incorporating recently discovered tissue-specific functions for next-generation therapies targeting a broad range of indications.
    Keywords:  Foxp3; IL-2 signaling; autoimmunity; cell engineering; clinical trials; inflammation; regenerative medicine; regulatory T (Treg) cell
    DOI:  https://doi.org/10.3389/fimmu.2026.1887951
  24. Int J Hematol. 2026 Nov 02.
      Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of relapsed or refractory B-cell malignancies and multiple myeloma. However, it involves multiple steps, from referral and eligibility assessment through leukapheresis, individualized manufacturing, bridging therapy, infusion, management of toxicities, and long-term follow-up, and requires multidisciplinary and interinstitutional health-care resources. Delay or failure at any step may compromise both access to CAR-T therapy and clinical outcomes. Establishing CAR-T therapy as sustainable routine care therefore requires greater efficiency and equitable standardization across the entire care pathway. Real-world evidence (RWE) can be used to evaluate effectiveness and safety in broader populations, including older patients and those with organ dysfunction, and also reveals the effects of care-process factors that are difficult to capture in clinical trials, such as manufacturing failure, pre-infusion attrition, vein-to-vein time, bridging therapy, bed utilization, infections, and late complications. This review summarizes major RWE for CAR-T therapies and discusses how RWE can support operational optimization from access through long-term follow-up. We further frame the integrated evaluation of basic biology, clinical data, and care processes, with continuous feedback of these findings to inform clinical and operational improvement, as "Cytotherapy Operational Science," and discuss its relevance to sustainable CAR-T therapy.
    Keywords:  Chimeric antigen receptor T-cell therapy; Cytotherapy operational science; Real-world evidence; Sustainability
    DOI:  https://doi.org/10.1007/s12185-026-04305-z
  25. Sci Bull (Beijing). 2026 Oct 27. pii: S2095-9273(26)01333-2. [Epub ahead of print]
      Despite the clinical success of immune checkpoint blockade and chimeric antigen receptor T-cell therapies, solid tumors frequently remain poorly responsive due to multi-step failures in initiating, maintaining, and executing immune responses in vivo. Overcoming these barriers requires organizing immune cues into productive biological relationships rather than simply intensifying systemic immune stimulation. This review examines how engineered nanobiotechnology addresses this central challenge by spatially and temporally coordinating key immune processes. Adopting a biology-driven and engineering-enhanced perspective, we analyze nanoscale interventions across four critical phases of antitumor immunity. Immune initiation engineering optimizes antigen processing and localized delivery to promote productive T-cell priming. To sustain these responses, targeted nanosystems reprogram lymphocytes and myeloid cells toward functional effector states in vivo. At the cellular interface, engineered platforms spatially coordinate immune recognition and effector engagement, while tumor microenvironment (TME) engineering remodels the suppressive niche to support tumor-specific immune activation. By organizing these advances through a process-centered engineering framework, we elucidate how nanobiotechnology can convert otherwise localized, transient, or poorly coordinated immune stimulation into integrated antitumor immunity. Finally, we discuss emerging clinical examples and translational requirements, highlighting how pharmacodynamic immune readouts, patient stratification, and manufacturable designs will drive next-generation nano-immunotherapies toward solid-tumor treatment.
    Keywords:  Cancer immunotherapy; Immune reprogramming; Nanobiotechnology; Tumor microenvironment
    DOI:  https://doi.org/10.1016/j.scib.2026.10.062
  26. Mol Ther Oncol. 2026 Dec 17. 34(4): 201359
      Gastrointestinal (GI) cancers, including colorectal and pancreatic cancers, remain among the most lethal cancers worldwide. These tumors often exhibit resistance to immune checkpoint inhibitors, largely due to microsatellite stability and a profoundly immunosuppressive tumor microenvironment (TME). While chimeric antigen receptor (CAR) T cell therapy has demonstrated curative potential in hematological cancers, its translation to solid tumors has been limited by challenges such as antigen heterogeneity, physical barriers to infiltration, and TME-mediated immunosuppression. Gene-editing technologies, including CRISPR-Cas9, have catalyzed the development of next-generation cellular immunotherapies. By precisely modifying T cells, natural killer (NK) cells, and mesenchymal stem/stromal cells (MSCs), it is possible to enhance their functionality, persistence, and safety. This review highlights the clinical progress of gene-edited cell therapies and specifically explores the synergistic "one-two punch" potential of engineered MSCs as TME remodeling platforms. By acting as localized delivery vehicles for cytokines or prodrug-activating enzymes, MSCs can modulate TME, thereby facilitating the infiltration and sustained cytotoxic activity of CAR T or CAR NK cells. Finally, we address critical translational challenges and propose future directions that integrate multi-omics to identify novel therapeutic agents for cellular immunotherapy in GI oncology.
    Keywords:  CAR T cells; CAR-NK cells; CAR-natural killer cells; MSCs; cell-based therapy; gastrointestinal cancer; mesenchymal stem/stromal cells
    DOI:  https://doi.org/10.1016/j.omton.2026.201359
  27. J Brown Hosp Med. 2026 ;5(4): 168550
      Immune checkpoint inhibitors (ICIs) and immune effector cell (IEC) therapies have transformed cancer treatment but cause distinct immune-mediated toxicities. This review synthesizes current evidence and consensus guidance on the immunobiology, clinical manifestations, and management of these complications. ICIs targeting CTLA-4, PD-1, PD-L1, and LAG-3 can disrupt immune tolerance, producing autoimmune-like immune-related adverse events (irAEs) affecting multiple organs, including the skin, gastrointestinal tract, endocrine system, lungs, liver, nervous system, heart, kidneys, and hematologic system. Management requires early recognition, exclusion of alternative diagnoses, and severity-based immunosuppression, typically corticosteroids with targeted agents for refractory disease such as infliximab, vedolizumab, mycophenolate mofetil, or abatacept. In contrast, IEC therapies, including CAR T-cell therapies and CD3-engaging bispecific antibodies, instead cause hyperinflammatory toxicities driven by rapid T-cell activation and cytokine amplification. Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) are the principal acute complications and are managed with close monitoring, organ support, IL-6 blockade with tocilizumab, and corticosteroids. Other complications include HLH-like hyperinflammatory syndromes, prolonged cytopenias, and infectious complications associated with immune dysfunction. As immunotherapies expand into earlier treatment settings and broader patient populations, effective toxicity management has become central to safe and successful cancer immunotherapy. Distinguishing autoimmune irAEs from hyperinflammatory IEC-associated syndromes provides a mechanistic framework for diagnosis and treatment. Continued integration of translational insights, standardized toxicity frameworks, and multidisciplinary clinical care will be essential to optimize patient outcomes while preserving the benefits of modern cancer immunotherapy.
    Keywords:  CRS; Cytokine release syndrome; ICANS; IEC; Immune effector cell associated neurotoxicity syndrome; Immune effector cell therapy; Immune related adverse events; Immunotherapy; irAE
    DOI:  https://doi.org/10.56305/001c.168550
  28. Pharm Stat. 2026 Nov-Dec;25(6):pii: e70131. [Epub ahead of print]25(6):
      In 2021, the FDA initiated Project Optimus to reform dose optimization and selection in early-phase oncology, highlighting that doses and schedules of new therapies are often inadequately characterized and that traditional dose-finding approaches should be revised. The project also encourages early and comprehensive exploration of multiple doses during clinical development and advocates for a more patient-centered approach incorporating not only toxicity but also the individual's response, biomarkers, pharmacokinetics/pharmacodynamics, or patient-reported outcomes to inform dosage decisions. We conducted a scoping review of the statistical and methodological literature on early-phase oncology trial designs in light of Project Optimus. The review aims to determine which key elements of the Optimus guidelines are incorporated into existing early-phase trial design methodologies and to assess remaining methodological gaps. It also aims to address the following question: What progress has been achieved so far, and what improvements can be made in light of the directives from Project Optimus? The review was organized according to the PRISMA-ScR guidelines. A total of 160 journals were finally retained, with 722 papers considered for the scoping review, published between January 1990 and September 2025. The database containing the reviewed papers is made available to the reader.
    Keywords:  adaptive design; dose optimization; dose‐finding; drug development; maximum tolerated dose; optimal dose
    DOI:  https://doi.org/10.1002/pst.70131
  29. Acta Pharm Sin B. 2026 Nov;16(11): 7184-7202
      Chimeric antigen receptor T (CAR-T) cell therapy has achieved remarkable success in treating hematologic malignancies, yet its efficacy in solid tumors remains constrained by multiple challenges. In this review, we summarize the main obstacles hindering CAR-T therapy in solid tumors, including suboptimal antigen targeting, poor trafficking and infiltration into tumor sites, and insufficient persistence of CAR-T cells. Furthermore, we discuss emerging strategies to overcome these hurdles, which can be categorized into two complementary aspects. The first focuses on optimizing intrinsic CAR-T properties for improved adaptation to the tumor microenvironment (TME), such as enriching less-differentiated T cell subsets, modifying CAR constructs, refining ex vivo culture conditions, and modulating specific genes or metabolic pathways through genetic or pharmacological interventions. The second approach aims to remodel the immunosuppressive TME by neutralizing inhibitory mediators, blocking immune checkpoints, and targeting immunosuppressive cell populations and stromal components. Importantly, we also summarized recent progress in in vivo CAR-T therapy. This review provides a comprehensive overview of the obstacles facing CAR-T in solid tumors, addressing both the underlying mechanisms and the translational potential of current and future strategies.
    Keywords:  Antigen targeting; CAR-T; CAR-T persistence; Cellular immunotherapy; In vivo CAR-T; Solid tumors; T cell infiltration; Tumor microenvironment
    DOI:  https://doi.org/10.1016/j.apsb.2026.07.047
  30. Eur J Clin Pharmacol. 2026 Nov 04. pii: 285. [Epub ahead of print]82(11):
      Drug repurposing can shorten selected stages of development by using prior pharmacological and clinical knowledge, but successful translation requires more than biological plausibility. This narrative review critically examines repurposing in oncology and rare diseases from a clinical pharmacology perspective, integrating candidate identification, achievable exposure, clinical evidence and implementation. Representative successful and unsuccessful examples are discussed to illustrate the importance of disease-relevant mechanisms, patient selection, meaningful endpoints and development feasibility. Computational methods and real-world data can support hypothesis generation and prioritisation, but require pharmacological validation and prospective assessment of clinical utility. The review also considers European and Italian regulatory pathways and the economic barriers affecting development of established medicines. We argue that repurposing should be evaluated through the coherence of its evidence package and a feasible development pathway, rather than prior approval status or low acquisition cost alone.Clinical trial number: not applicable.
    Keywords:  Artificial intelligence; Clinical pharmacology; Drug repurposing; Oncology; Rare diseases; Real-world evidence
    DOI:  https://doi.org/10.1007/s00228-026-04215-3
  31. Front Immunol. 2026 ;17 1956545
       Background: Antigen-specific regulatory T-cell therapies seek to control donor-reactive immunity while preserving broader immune protection. The available platforms differ substantially in cellular composition, mode of antigen recognition, manufacturing requirements, and maturity of clinical evidence.
    Scope: This narrative Mini Review compares donor-cell expansion, costimulation-blockade products, peptide-based targeting of indirect allorecognition, CAR- and TCR-engineered Tregs, and Tr1-enriched products. Evidence is distinguished as ex vivo or mechanistic, preclinical in vivo, human non-kidney, kidney feasibility and safety, or suggestive of clinical activity.
    Key insights: No platform is likely to suit every transplant setting. Donor-cell approaches provide broad antigenic coverage but require individualized donor material. Peptide and receptor-defined approaches offer precision and donor-independent manufacture but are constrained by antigen processing, HLA restriction, or incomplete coverage. Early CAR-Treg studies provide preliminary safety and proof-of-mechanism observations, not evidence of operational tolerance. Culture conditions, accompanying immunosuppression, and product-specific safety risks must be considered together.
    Conclusions: Progress will require consistent nomenclature, mechanism-linked potency assays, quantitative reporting of clinical studies, and operational measures of persistence, regulatory stability, donor-specific function, graft engagement, and clinical durability. The near-term goal is safe and sustained immunosuppression minimization. Operational tolerance must be demonstrated rather than inferred.
    Keywords:  alloantigen; antigen-specific cell therapy; immune regulation; immune tolerance; kidney transplantation; regulatory T cells
    DOI:  https://doi.org/10.3389/fimmu.2026.1956545
  32. Crit Rev Oncol Hematol. 2026 Nov 02. pii: S1040-8428(26)00566-4. [Epub ahead of print]228 105679
      Cellular and gene-based therapies are being investigated as potential strategies to address current treatment limitations in breast cancer. Adoptive cell therapies, such as CAR-T, TCR-T, TILs and NK cell-based therapies, are currently under investigation for their ability to selectively target tumor-associated antigens. Also, CRISPR/Cas9-mediated genome editing is being investigated as a strategy to enhance T cell persistence, improve tumor infiltration, and increase resistance to immunosuppressive signaling. Although cellular and gene-based therapies have transformed the treatment of hematologic malignancies, their application in breast cancer remains limited by antigen heterogeneity, immune exclusion, and the immunosuppressive tumor microenvironment. Among current approaches, TIL-based therapies have provided some of the clearest evidence of clinical activity selected patients, whereas the clinical efficacy of CAR-T and gene-editing strategies as standalone interventions remains uncertain. Future progress may depend on biomarker-guided, combinatorial approaches rather than single-modality therapies. This review examines the current applications, clinical evidence, and limitations of these approaches in breast cancer.
    Keywords:  Adoptive cell therapy; Breast cancer; Cellular therapy; Gene editing; Immunotherapy
    DOI:  https://doi.org/10.1016/j.critrevonc.2026.105679
  33. Int J Nanomedicine. 2026 ;21 630008
       Introduction: Chimeric antigen receptor T (CAR-T) cell therapy has great potential but is limited by off-target effects and cytokine release syndrome. To address these challenges, we developed a mesothelin-targeted switchable CAR-T cell system whose activity can be externally controlled by near-infrared (NIR) light-responsive liposomes.
    Methods: We constructed mesothelin-targeted switchable CAR-T cells via lentiviral transduction. A NIR-responsive liposomal formulation was prepared to encapsulate a small-molecule switch agent (rapamycin or AP21967) for controlled release upon NIR irradiation. By encapsulating a NIR-triggerable photosensitizer, the liposomes became photo-labile, and exposure to 730 nm light induced lipid peroxidation, consequently allowing drug release. The switchable CAR-T cells were co-cultured with mesothelin-expressing ovarian cancer cells (OVCAR-3) under various conditions, with or without NIR irradiation. Cytotoxicity was assessed by LDH release assay, and cytokine secretion (TNF-α and IL-2) was measured by ELISA.
    Results: The switchable CAR-T cells exhibited minimal baseline cytotoxicity in the absence of the inducing agent. Upon NIR irradiation, the liposomes released the encapsulated switch agent, which activated the CAR-T cells in a concentration-dependent manner. NIR-triggered activation significantly enhanced the secretion of TNF-α and IL-2 and potentiated the killing effect against mesothelin-positive ovarian cancer cells in vitro.
    Conclusion: Our findings demonstrate that the combination of switchable CAR-T technology with NIR-responsive liposomes enables spatiotemporally controlled CAR-T activation, offering a potential strategy to mitigate off-target toxicity and facilitating the clinical application of CAR-T therapy in solid tumors.
    Keywords:  chimeric antigen receptor T; liposomes; mesothelin; near-infrared light-responsive
    DOI:  https://doi.org/10.2147/IJN.S630008
  34. Curr Probl Diagn Radiol. 2026 Oct 31. pii: S0363-0188(26)00204-5. [Epub ahead of print]
      Hallucinations generated by large language models (LLMs) represent an emerging safety top event in radiology, where subtle interpretive errors can rapidly propagate into clinical decisions. Although these systems demonstrate remarkable linguistic fluency, their underlying probabilistic architecture is, in some cases, not aligned with the demands of diagnostic intelligence, factual reliability, or safety standards. This work presents a comprehensive review describing the pathways that lead to hallucinations in radiology domain generative LLMs, mapping the risks derived from model architecture, data quality, black-box opacity, and automation bias. It also identifies the preventive strategies required to control these risks, including legal and governance safeguards, rigorous data curation protocols, explainability and simulation frameworks, and structured human oversight. This review shows how hallucinations may distort diagnostic reasoning, generate fictitious clinical data, and precipitate erroneous management decisions with potential patient harm, underscoring the need for controlled deployment strategies before integrating generative AI into radiological workflows.
    Keywords:  Hallucinations; Large language model; Radiology
    DOI:  https://doi.org/10.1067/j.cpradiol.2026.10.014
  35. Acta Pharm Sin B. 2026 Nov;16(11): 7228-7244
      The clinical translation of ex vivo CAR-T therapy is constrained by its complex manufacturing processes, limited treatment accessibility, and the toxicities associated with lymphodepleting chemotherapy. In vivo CAR-T strategies, which utilize viral or non-viral vectors to reprogram a patient's T cells directly in situ genetically, offer a promising alternative. This review provides a systematic examination of the critical barriers impeding the advancement of in vivo CAR-T therapy. We first summarize the factors influencing the targeting ability of both the delivery system and the CAR molecule. As for the vectors, we detail how the composition and physicochemical properties of LNPs shift their tropism from the liver to the spleen and provide a critical comparison of active targeting strategies based on different T-cell surface antigens. As for the CAR molecule, target selection is primarily dictated by the intended disease. Furthermore, we discuss the determinants of poor CAR-T cell persistence, including unstable mRNA payloads and exhaustion-associated signaling pathways. Addressing the challenges of solid tumor treatment, we dissect the multifaceted role of the tumor microenvironment. Finally, this review illustrates the mechanisms underlying overactivation and immunogenicity triggered by both viral and non-viral vector systems.
    Keywords:  Clinical translation; Immunogenicity; In vivo CAR-T therapy; Lentivirus; Lipid nanoparticles; T cell exhaustion; Targeted delivery; Tumor microenvironment
    DOI:  https://doi.org/10.1016/j.apsb.2026.08.030
  36. Sci Immunol. 2026 Nov 06. 11(125): eaed1027
      In vivo cell engineering enables the direct programming of immune cells inside patients. Instead of isolating, modifying, and reinfusing cells, therapeutic instructions are delivered directly to selected immune cells through lipid nanoparticles or viral vectors. This approach could facilitate rapid and scalable deployment of varied immune cell therapies across disease contexts. Early clinical studies in oncology and autoimmunity demonstrate increasing technical and clinical feasibility. The next challenge lies in enhancing precision to ensure that vectors reach the target cell type and tissue, deliver the appropriate payload, and produce desired transient or durable activity. Progress in targeting ligands, vector design, biodistribution control, and genome editing is beginning to address these barriers. Ensuring safety against immunogenicity, inflammatory toxicity, off-target editing, and uncontrolled persistence remains a central priority. By mastering these constraints, in vivo engineering could turn endogenous immune cells into therapeutic agents generated directly in the body, expanding cell therapy to diseases refractory to current modalities.
    DOI:  https://doi.org/10.1126/sciimmunol.aed1027
  37. Front Genet. 2026 ;17 1918845
       Background: Pediatric solid tumors, including neuroblastoma (NB), emerge within an immature immune system where inherited immunogenetic variation may affect tumor onset and progression. Differences in HLA system are central to antigen presentation and immune recognition. However, their role in pediatric solid tumors is less clearly defined than in hematologic malignancies, and current evidence remains limited.
    Objective: This review summarizes evidence linking inherited HLA class I and II variation to NB susceptibility and clinical outcomes in pediatric NB. Tumor-associated HLA alterations, including reduced HLA expression and antigen-presentation defects that contribute to immune escape, are discussed as distinct but biologically related mechanisms.
    Methods: A structured synthesis of case-control and cohort studies evaluating HLA alleles, haplotypes, and expression in pediatric NB was performed. Data were organized by population, sample size, HLA locus, and association strength, and interpreted using concepts of antigen presentation, immune editing, and tumor microenvironment interactions.
    Results: Current evidence suggests that HLA-A, HLA-B, and HLA-C class I alleles and haplotypes influence susceptibility through effects on cytotoxic T-cell and natural killer cell function, while the strongest class II associations involve DRB1-DQB1 region, including DQB1*05:02 and DRB1*16:01, which regulate CD4+ T-cell responses and inflammatory signaling. Some associations appeared subtype-specific, particularly in MYCN-amplified tumors, although evidence stratified by stage, age, and risk group remains limited. Beyond susceptibility, specific class I variants were associated with overall survival and progression-free survival including among patients receiving anti-GD2 immunotherapy, while HLA-KIR interactions and transplantation-related immunogenetic parameters were associated with disease progression and survival following hematopoietic stem cell transplantation. Separately, tumor-associated reductions in human leukocyte antigen expression or antigen-processing capacity may facilitate immune evasion by limiting effective antitumor immune recognition, though direct evidence remains limited.
    Conclusion: HLA polymorphisms, particularly within HLA-A, HLA-B, HLA-C, DRB1, and DQB1 loci, are plausible, but not fully confirmed determinants of NB susceptibility and clinical outcome, with the strongest evidence relating to OS and PFS, clinical outcomes among patients receiving anti-GD2 immunotherapy, and outcomes following stem cell transplantation.
    Keywords:  HLA; HLA class I; HLA class II; antigen presentation; neuroblastoma; pediatric solid tumors
    DOI:  https://doi.org/10.3389/fgene.2026.1918845
  38. J Vis Exp. 2026 Nov 05.
      The fragmentation of sensitive medical data across institutions and stringent privacy regulations creates isolated data silos, hindering the development of robust AI-driven healthcare solutions. Existing approaches often lack sufficient trust mechanisms, comprehensive auditability, and dynamic access control for multi-center collaboration. Goal: This protocol aims to resolve the tension between collaborative utility and data sovereignty by integrating federated learning (FL) with blockchain technology, providing a secure, auditable, and scalable framework for medical data sharing. The framework employs a tripartite architecture: cryptographic FL with adaptive regularization and Paillier homomorphic encryption for privacy-preserving local training; a multi-channel, tiered-sharding blockchain for decoupled access control, data provenance, and FL operation logging; and a dynamic privacy-computation coordination mechanism that adapts differential privacy and cryptographic protocols based on data sensitivity and hardware capability. The workflow follows a sequential set of steps, including data preprocessing, local encrypted gradient generation, blockchain-backed secure aggregation, and global model updating. Under experimental conditions, the framework achieved 92.5% model accuracy after 20 training rounds and supported up to 30 nodes. No raw data exposure was detected, and tamper detection succeeded in all evaluated test cases. The architecture reduced computational overhead by 41% compared to a centralized baseline, achieved 96% automated regulatory compliance for audited access approvals, and demonstrated linear scalability, with the block generation interval stabilizing at 4.2 s.
    DOI:  https://doi.org/10.3791/70931
  39. Front Immunol. 2026 ;17 1988247
      Immune checkpoint blockade has reshaped cancer therapy, but durable responses remain limited by insufficient antigen release, poor T-cell infiltration, immunosuppressive tumor microenvironments, and systemic immune-related toxicity. Ultrasound-responsive nanoplatforms provide a spatiotemporally controllable strategy to overcome these barriers by exploiting deep tissue penetration, focal activation, and repeatable external triggering. In this review, we summarize recent experimental advances in sonosensitizer-based and ultrasound-triggered nanoplatforms for cancer immunotherapy. These systems integrate sonodynamic immunogenic cell death, pyroptosis, ferroptosis, necroptosis, cGAS-STING activation, immune checkpoint blockade, mRNA delivery, gas therapy, and tumor microenvironment remodeling to convert immune-cold tumors into immune-responsive lesions. We further discuss cancer type-specific applications in hepatocellular carcinoma, pancreatic cancer, glioblastoma, triple-negative breast cancer, colorectal cancer, bladder cancer, and other solid tumors, emphasizing how ultrasound-responsive designs can be matched to distinct anatomical and immunological barriers. Finally, we highlight key translational challenges, including long-term biosafety, controllable immune activation, ultrasound parameter standardization, scalable manufacturing, and clinically compatible combination strategies. Ultrasound-responsive nanoplatforms are emerging not merely as drug carriers, but as programmable immune-engineering systems capable of coordinating when, where, and how antitumor immunity is activated within the tumor microenvironment.
    Keywords:  STING activation; cancer immunotherapy; sonodynamic therapy; tumor microenvironment; ultrasound-responsive nanoplatforms
    DOI:  https://doi.org/10.3389/fimmu.2026.1988247
  40. Int J Nanomedicine. 2026 ;21 644095
      Cancer nanomedicine offers programmable platforms for diagnosis, imaging, drug and gene delivery, and theranostics, but its clinical performance is constrained by tumor heterogeneity, complex nano-bio interactions, and interpatient variability. Artificial intelligence (AI) provides a means to integrate physicochemical, biological, imaging, molecular, and clinical data to improve the design and application of nanoscale cancer technologies. This Review examines the convergence of AI and nanotechnology across cancer diagnosis, therapeutic selection, treatment optimization, monitoring, drug development, and clinical translation, with particular emphasis on materials design and biological performance. AI-based approaches can support early detection, patient stratification, response and toxicity prediction, and rational therapeutic development. In parallel, nanoplatforms, including liposomes, polymeric nanoparticles, dendrimers, metallic and inorganic nanoparticles, biomimetic systems, and stimuli-responsive carriers, can improve pharmacokinetics, enhance tumor exposure, reduce systemic toxicity, and enable controlled delivery of diverse payloads. Their integration may advance precision nanomedicine by guiding nanoparticle composition, size, surface properties, targeting ligands, biodistribution, tumor accumulation, cellular uptake, protein-corona formation, release kinetics, toxicity, and therapeutic response. Conversely, nanodiagnostic and nanotheranostic systems can generate imaging, molecular, pharmacokinetic, and response data for AI-assisted patient selection and adaptive treatment monitoring. Translation will require standardized datasets, reproducible nanoparticle characterization, scalable manufacturing, explainable and externally validated models, regulatory clarity, long-term safety assessment, and equitable implementation. Together, AI-guided nanotechnology provides a framework linking materials design, biological interactions, and patient-specific cancer therapy.
    Keywords:  AI-guided nanomedicine; adaptive cancer therapy; machine learning; nanoparticle drug delivery; nanotheranostics; precision oncology
    DOI:  https://doi.org/10.2147/IJN.S644095
  41. Ren Fail. 2026 Dec;48(1): 2753269
      Acute T cell-mediated rejection (TCMR) remains an important cause of early and intermediate-term graft dysfunction after kidney transplantation. As effector cells that bridge innate and adaptive immunity, macrophages are deeply implicated in the initiation, progression, and fibrotic sequelae of TCMR. This review synthesizes their multifaceted pathological roles: antigen presentation and T cell activation during early rejection, pro-inflammatory polarization driving parenchymal injury, chemokine-mediated recruitment that sustains immune infiltration, and macrophage-to-myofibroblast transition (MMT) underlying interstitial fibrosis in chronic graft deterioration. Because conventional immunosuppression is systemic and incompletely addresses the intragraft immune microenvironment, we further examine chimeric antigen receptor macrophages (CAR-Ms) as an emerging strategy for TCMR intervention. Building on current mechanistic insight, we propose two engineering approaches: targeted-elimination CAR-Ms designed to recognize and clear pathogenic effector immune cells, and tolerance-inducing resident CAR-Ms engineered to suppress inflammation and fibrosis while promoting tolerance. Together, these macrophage-engineering strategies provide a conceptual approach to reshaping the renal allograft immune microenvironment and improving long-term graft survival.
    Keywords:  Renal transplantation; T cell-mediated rejection; chimeric antigen receptor macrophages; immune microenvironment; macrophage-to-myofibroblast transition; macrophages
    DOI:  https://doi.org/10.1080/0886022X.2026.2753269
  42. Pharmgenomics Pers Med. 2026 ;19 602618
       Background: Hyperuricemia is increasingly prevalent and is closely associated with gout and several cardiometabolic and renal disorders. Although pharmacological development in this field is expanding, the overall structure and recent evolution of the global development pipeline remain incompletely characterized. This study aimed to characterize recent trends in drug development and clinical research for hyperuricemia.
    Methods: Hyperuricemia-related drug-development records were retrieved from the Pharmaprojects database from database inception to July 31, 2025. Records were screened according to disease classification, pharmacological relevance, and development status. After screening and data verification, 69 eligible records were included. Development stage, geographical distribution, therapeutic class, mechanism of action, molecular target, and commencement date were analyzed descriptively.
    Results: A total of 69 eligible drug-development records were included. The pipeline was predominantly concentrated in preclinical and early clinical development, with preclinical programs accounting for 31.88%, Phase I for 20.29%, Phase II for 18.84%, and Phase III for 17.39%. China and the United States represented important contributors to the identified development activities. The development portfolio was dominated by gout-related therapies but showed increasing mechanistic diversity. URAT1-related approaches were prominent, and SLC22A12 was the most frequently represented molecular target. Xanthine oxidase-, uricase-, and inflammation-related mechanisms were also represented.
    Conclusion: The global development pipeline for hyperuricemia remains weighted toward preclinical and early clinical stages but is becoming increasingly diverse in therapeutic mechanisms and molecular targets. Further late-stage clinical evaluation, multicenter studies, and long-term safety assessment are required to establish the clinical value of emerging therapeutic strategies.
    Keywords:  clinical trials; drug; hyperuricemia; treatment
    DOI:  https://doi.org/10.2147/PGPM.S602618
  43. Front Immunol. 2026 ;17 1996626
      Human leukocyte antigen (HLA) associations anchor genetic susceptibility to autoimmune hepatitis (AIH). Connecting this susceptibility to the immune reactions that sustain liver injury remains a central challenge. Recent antigen-specific experiments and tissue analyses provide complementary insights into recognition and injury. This Mini Review examines how population-specific HLA associations, SepSecS-reactive lymphocytes and intrahepatic immune states inform the relationship between antigen recognition and inflammatory amplification. The evidence reveals three unresolved relationships between susceptibility, recognition and injury. Class II-restricted autoreactivity and conditionally independent class I associations in Han Chinese AIH implicate potentially complementary immune pathways. Antigen-specific T-cell responses extend beyond the boundaries defined by autoantibody status. Receptor specificity and the capacity to sustain tissue injury require distinct functional tests. We evaluate antigen-presentation experiments, receptor studies and tissue profiling, distinguishing human observations from mechanistic models. The synthesis supports a model in which heterogeneous antigen-specific responses may converge on shared inflammatory processes. Priorities include linking genetic risk to natural antigen presentation and defining autoreactive clone function in liver tissue. Matched perturbation experiments should then test antigen dependence alongside cytokine-dependent injury. Resolving these questions would clarify which mechanisms require antigen-specific intervention and which reflect downstream inflammatory amplification.
    Keywords:  HLA; SEPSECS; T-cell receptor; antigen presentation; autoantigens; autoimmune Hepatitis; liver inflammation
    DOI:  https://doi.org/10.3389/fimmu.2026.1996626
  44. Front Immunol. 2026 ;17 1964649
      Cancer-testis antigens (CTAs) are attractive targets for tumour immunotherapy due to their restricted expression in human malignancies and broad population-level prevalence. However, naturally occurring CTA-reactive T cells are often exhausted or functionally compromised, limiting their direct therapeutic utility. Here, using a non-viral orthotopic TCR replacement system, we systematically evaluated two patient-derived HLA-A*02:01-restricted TCRs specific for the synovial sarcoma X breakpoint 2 (SSX2) epitope SSX241-49 (KASEKIFYV). Although both TCRs conferred SSX2 specificity, one displayed markedly higher functional avidity and superior antigen responsiveness. Primary CD8+ T cells redirected with this high-avidity TCR showed CD8-independent recognition, enhanced tetramer binding, and stronger functional responses against SSX2-expressing tumour cells. Notably, the same TCR also redirected CD4+ T cells toward the MHC-I-restricted SSX2 epitope, inducing polyfunctional cytokine release and direct tumour cytotoxicity. Moreover, it remained highly functional when introduced into unconventional T cell subsets, including NKT and γδ T cells, thereby expanding the range of potential cellular platforms for TCR-based therapeutics. Together, these findings identify a naturally derived, high functional avidity SSX2-reactive TCR with broad activity across conventional and unconventional T cell subsets, supporting its further development for future TCR-T cell-based immunotherapies.
    Keywords:  T cell engineering; T cell receptor (TCR); TCR-T cell; adoptive cell therapy (ACT); tumour immunotherapy; tumour-reactive T cell
    DOI:  https://doi.org/10.3389/fimmu.2026.1964649
  45. Front Genet. 2026 ;17 1987469
      Pharmacogenomics (PGx) is a cornerstone of precision medicine, enabling individualized drug therapy by identifying genetic factors that influence drug disposition and response. However, genotype-based predictions frequently fail to reflect actual drug-metabolizing capacity because enzyme activity can be modified by non-genetic factors, including concomitant medications, inflammation, organ dysfunction, aging, smoking, pregnancy, and other environmental influences. Phenoconversion can generate substantial discrepancies between genotype-predicted and observed metabolic phenotypes, contributing to adverse drug reactions, therapeutic failure, and reduced clinical utility of pharmacogenomic testing. The identification of phenoconversion remains challenging because the relevant determinants are often dispersed across multiple sources of information, including medication records, laboratory data, diagnostic information, and unstructured clinical notes within electronic health records. Recent advances in large language models (LLMs) offer new opportunities to address this limitation by retrieving, organizing, and contextualizing heterogeneous clinical and pharmacogenomic information. Beyond identifying drug-drug-gene and drug-gene-environment interactions, LLM-enabled systems may support dynamic phenotype assessment by modeling metabolic capacity as a continuously evolving characteristic rather than a static genotype-derived category and by identifying relevant modifiers even for drugs without actionable pharmacogenomic recommendations. This review examines the biological basis and clinical significance of phenoconversion and discusses the potential role of LLMs in bridging the gap between genetic predisposition and real-world drug response. We highlight the emerging concept of dynamic phenotype models that combine genetic, clinical, and environmental determinants of drug metabolism and may support more precise, context-aware pharmacotherapy.
    Keywords:  drug-drug-gene interactions; electronic health records; large language models; pharmacogenomics; phenoconversion; precision pharmacotherapy
    DOI:  https://doi.org/10.3389/fgene.2026.1987469
  46. Orphanet J Rare Dis. 2026 08 05. pii: 394. [Epub ahead of print]21(1):
       BACKGROUND: Health technology assessment (HTA) is widely used to inform coverage and reimbursement decisions in health systems by integrating evidence on clinical effectiveness, safety, cost-effectiveness, and broader social considerations. However, the application of conventional HTA frameworks to rare diseases remains challenging due to limited clinical evidence, substantial uncertainty, and ongoing debates regarding the appropriateness of standard evaluation criteria. In this context, this study aimed to identify and synthesize additional criteria and their underlying justifications proposed and/or applied in HTA-based decision-making for rare diseases, and to examine the extent to which these criteria have been adopted by HTA agencies across countries.
    METHODS: The protocol was registered in PROSPERO (CRD420251115351). We conducted an overview of reviews in accordance with the Cochrane Handbook and the PRIOR statement, complemented by a structured grey literature search of health technology assessment agencies and Ministries of Health affiliated with INAHTA and RedETSA. Systematic and scoping reviews, as well as institutional documents addressing criteria used in coverage decisions for rare diseases, were included. Findings were synthesized narratively, with criteria grouped into adapted standard and additional categories, and implementation patterns examined across different health system types.
    RESULTS: Seventeen reviews and multiple institutional documents from eleven countries were included. Seven standard health technology assessment criteria and ten additional criteria were identified. Most jurisdictions reported adaptations of conventional health technology assessment approaches to address uncertainty and ethical concerns associated with rare diseases; however, only a limited number had operationalized a comprehensive set of additional criteria. Disease severity and therapeutic advantage were the most frequently applied additional criteria across countries, whereas treatment characteristics and risk-sharing mechanisms were inconsistently reported. Evidence specific to ultrarare diseases was scarcer, suggesting that decision-making for ultrarare conditions likely relies on criteria applied to rare diseases.
    CONCLUSIONS: Health technology assessment for rare and ultrarare diseases is characterized by selective and pragmatic adaptations rather than the use of unified alternative frameworks.
    REGISTRATION: PROSPERO CRD420251115351.
    Keywords:  Decision making; Health equity; Health policy; Health technology assessment; Patient navigation; Rare diseases; Ultrarare diseases
    DOI:  https://doi.org/10.1186/s13023-026-04521-0
  47. Cancer Res. 2026 Nov 04.
      Adoptive cell therapies using chimeric antigen receptor or T cell receptor-transgenic T cells (TCR-T) are effective in treating hematological malignancies but have limited efficacy in solid tumors, particularly brain tumors. A major challenge of adoptive T cell therapy in brain tumors is lack of access to the target antigen, which is necessary for restimulation and persistence. Here, we addressed this challenge by using an mRNA vaccine encoding the cognate antigen to induce in vivo restimulation of transferred TCR-T cells in glioma models. Delivery of mRNA encoding the immunodominant MHC class I ovalbumin epitope SIINFEKL to splenic dendritic cells initiated strong expansion of adoptively transferred ovalbumin-specific OT1 CD8+ T cells to up to 80% of all circulating CD8+ T cells. RNA vaccination markedly improved T cell infiltration and retained interferon-stimulated gene signature in the brain, suppressing glioblastoma growth. The therapeutic efficacy of this approach was further demonstrated in an experimental model for a first-in-class TCR-T cell therapy targeting an HLA-A2-restricted immunodominant epitope of the human glioblastoma stemness antigen PTPRZ1. Co-administration of human dendritic cells transfected with PTPRZ1-mRNA led to rejection of orthotopically implanted primary human gliomas endogenously expressing PTPRZ1 and HLA-A2 after adoptive transfer of PTPRZ1-TCR-T cells. In summary, these findings indicate that mRNA vaccines can boost TCR-T cell therapy against glioblastoma.
    DOI:  https://doi.org/10.1158/0008-5472.CAN-26-0760
  48. Res Sq. 2026 Oct 27. pii: rs.3.rs-11447687. [Epub ahead of print]
      Diffuse intrinsic pontine glioma (DIPG) and diffuse midline glioma (DMG) are lethal pediatric central nervous system (CNS) tumors with a median survival of 11 months. Despite advancements in translating chimeric antigen receptor (CAR) T cells for these patients, efficacy may be constrained by antigen heterogeneity and immune escape. We conducted a first-in-human, phase 1 trial (BrainChild-04; NCT05768880) evaluating repetitive intracerebroventricular (ICV) administration of a multi-antigen targeting CAR T cell product directed against B7-H3, EGFR806, HER2 and IL13Rα2 (quad-CAR T cells) for children and young adults with DIPG/pontine DMG (Arm A) and recurrent or refractory CNS tumors (Arm B). Here we report results from Arm A. Primary endpoints were feasibility, safety, and determination of the maximally tolerated dose regimen (MTDR). Secondary endpoints included CAR T cell distribution and preliminary clinical activity. Correlative analyses assessed CAR T cell kinetics and cytokine dynamics in cerebrospinal fluid (CSF). Twenty-six patients were enrolled with 100% manufacturing success rate. Twenty-one patients received at least one infusion (median 8/patient, range 3-56). No dose-limiting toxicities occurred in the dose-finding period, and treatment was tolerable with predominantly grade 1-2 adverse events, including fever (95%), headache (86%), and fatigue (81%). One dose-limiting toxicity (acoustic nerve disorder) occurred outside the evaluation window. Repetitive ICV dosing was feasible, and most of the infused patients (86%) initiated two or more treatment courses (median 4). CAR T cells were detected in CSF in 100% of patients, across serial courses in 76% of patients, with evidence of detection across sequential courses, particularly at higher dose levels. Cytokine profiling demonstrated dynamic immune activation within the CNS. Median survival from initial CAR T infusion was 8.6 months (95% CI: 5.2-10.3). All deaths were due to disease progression. Repetitive ICV administration of quad-CAR T cells is feasible and tolerable in children and young adults with DIPG/DMG. This study represents the first clinical application of quad-antigen targeting CAR T cells and confirmed feasibility in manufacturing and preliminary evidence of biologic activity in the CNS. These findings support further evaluation of multi-antigen CAR T strategies to address tumor heterogeneity of antigen expression as a likely barrier to CAR T cell efficacy in patients with CNS tumors.
    DOI:  https://doi.org/10.21203/rs.3.rs-11447687/v1
  49. Cell Rep Med. 2026 Nov 05. pii: S2666-3791(26)00545-8. [Epub ahead of print] 103128
      T cells engineered to express recombinant T cell receptors (TCRs) or chimeric antigen receptors (CARs) can induce durable clinical responses in solid and hematological malignancies. However, manufacturing is resource intensive and often yields highly differentiated, exhausted T cell products. To address this, we developed an antigen-scaffold (Ag-scaffold) technology that presents cognate antigen alongside stimulatory cytokines to preferentially expand genetically engineered T cells. We expanded CRISPR-Cas9- and lentivirally engineered TCR T cells with peptide MHC (pMHC)-presenting Ag-scaffolds and anti-CD19 CAR T cells with CD19-presenting Ag-scaffolds. By applying cognate pMHC Ag-scaffolds, we achieved on average 69% (±22%) antigen-specific T cells after 14 days of culture with a cytotoxic, proliferative profile. Ag-scaffold expansion enhanced initial TCR and CAR cytotoxicity; repeated rechallenges showed sustained control. In vivo, Ag-scaffold-expanded CRISPR-Cas9-engineered NY-ESO-1-specific TCR T cells and anti-CD19 CAR T cells also showed improved tumor control in lymphoma and solid tumor xenograft models compared to cells expanded with IL2/7/15.
    Keywords:  CAR T cells; CRISPR; Cas9; T cell engineering; TCR T cells; TCR complex; artificial antigen-presenting scaffolds; chimeric antigen receptor; interleukin 2; peptide major histocompatibility complex
    DOI:  https://doi.org/10.1016/j.xcrm.2026.103128
  50. Biomark Res. 2026 Oct 31. pii: 157. [Epub ahead of print]14(1):
      The advent of immunotherapy has profoundly transformed the therapeutic landscape of hematologic malignancies. A broad range of immune-based strategies, including immune checkpoint inhibitors and adoptive cell therapies based on both T cells and natural killer (NK) cells, have achieved unprecedented clinical outcomes in several lymphoid and myeloid neoplasms. Emerging approaches such as genetically engineered immune cells, including chimeric antigen receptor (CAR)-modified T and NK cells, are further expanding therapeutic opportunities. However, substantial heterogeneity in treatment response remains a major challenge, with a significant proportion of patients experiencing primary resistance, relapse, or severe immune-related toxicities. Accurate identification of predictive and prognostic biomarkers is therefore essential to optimize patient selection, improve therapeutic efficacy, and minimize treatment-related toxicity. Numerous biological parameters have been investigated, including clinical prognostic scores, systemic inflammatory indices, tumor burden markers, immune-cell subsets, cytokine profiles, genetic and molecular alterations, and features of the tumor microenvironment. Emerging evidence indicates that both host-related factors and tumor-intrinsic characteristics shape therapeutic responses to immunotherapy across hematologic cancers. Among the most promising biomarkers are inflammatory indices derived from peripheral blood counts, such as the neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, monocyte-to-lymphocyte ratio, systemic immune-inflammation index, prognostic nutritional index, and Glasgow Prognostic Score. In parallel, immune-monitoring approaches assessing the functional competence, phenotype, and activation status of both T and NK cells, together with cytokine signatures, immune checkpoint expression, and other markers of immune competence, are increasingly recognized as valuable tools for predicting therapeutic response, resistance, and immune-related toxicity. This review summarizes the current evidence on prognostic scores and biomarkers associated with immunotherapy outcomes in hematologic malignancies. We discuss their biological rationale, clinical relevance, current limitations, and potential integration into contemporary treatment strategies. Finally, we highlight emerging perspectives, including multi-omics profiling, artificial intelligence-driven predictive models, and dynamic biomarker-guided approaches, which are expected to advance precision immuno-oncology and enable increasingly personalized immune-based treatment algorithms.
    Keywords:  Bispecific antibodies; CAR- T cells; Cytokines; Hematologic malignancies; Immune checkpoint inhibitors; Immunotherapy; Inflammation; Predictive biomarkers; Prognostic scores
    DOI:  https://doi.org/10.1186/s40364-026-01033-8
  51. Curr Opin HIV AIDS. 2026 Nov 06.
       PURPOSE OF REVIEW: Natural killer (NK) cells are attractive effectors for HIV cure-directed strategies, combining target recognition, antibody-dependent cellular cytotoxicity, and expansion compatibility with scalable allogeneic manufacture. This review evaluates NK cell gene-engineering and NK-boosting approaches as coordinated anti-HIV strategies rather than isolated enhancements.
    RECENT FINDINGS: HIV-directed NK cell genetic modifications now include fixed CD4-based chimeric antigen receptors (CARs,) a universal adaptor CAR, CD64-engineered antibody-armed NK cells, or added lymph node homing approaches centered on CXCR5, CCR7, or CD62L. Complementary strategies seek to augment NK activity through HIV-specific binders, eCD4-Ig, interleukin (IL)-15-containing TriKEs, or blockade of inhibitory receptors such as NKG2A, TIGIT or KLRG1. However, progress remains uneven as most engineered products are supported only by in vitro or animal studies. Importantly, Env-directed recognition depends on sufficient antigen expression which is often dependent on latency reversal, tissue access remains incompletely validated, and NK checkpoint modulation has not yet been tested clinically in HIV.
    SUMMARY: A clinically deployable HIV-directed NK cell product or combination therapy will require coordinated strategies addressing target recognition, trafficking, persistence, retained function, and safety. Development milestones should include demonstrable tissue localization, controlled persistence, and safety of engineered NK cells. If met, the goal for future endpoints would be the demonstration of a significant reduction of intact or inducible reservoir and delayed rebound during analytical treatment interruption as progress toward a functional cure for HIV.
    Keywords:  Fc receptor; HIV cure; chimeric antigen receptor-natural killer; natural killer cell engineering; tissue trafficking; viral reservoir
    DOI:  https://doi.org/10.1097/COH.0000000000001085
  52. Expert Rev Hematol. 2026 Nov 06. 1-12
       INTRODUCTION: Acute graft-versus-host disease (aGVHD) remains a leading cause of morbidity and non-relapse mortality after allogeneic hematopoietic cell transplantation. Despite progress in prophylactic strategies, its management remains challenging: corticosteroids are still the mainstay of first-line care, yet a substantial proportion of patients fail to achieve durable responses, underscoring the need for more effective and less toxic alternatives.
    AREAS COVERED: This review outlines the current approach to aGVHD, from first-line management to steroid-refractory disease and beyond. It covers corticosteroid optimization, the established role of ruxolitinib in the steroid-refractory setting, and the use of extracorporeal photopheresis in selected patients. Cellular, microbiome-based, cytokine-directed, and regenerative strategies acting on complementary pathogenic mechanisms are also discussed. The literature was identified through a PubMed search using the terms 'acute graft-versus-host disease' and 'treatment,' including publications up to 30 June 2026, supplemented by manual screening of reference lists.
    EXPERT OPINION: Ruxolitinib has reshaped the management of steroid-refractory aGVHD, although important unmet needs persist. Future progress will depend not only on new agents but on smarter use of existing options: minimizing steroid exposure, refining sequencing, and integrating combinations earlier. Biomarker-guided risk stratification may ultimately support a more individualized approach, improving disease control while limiting toxicity.
    Keywords:  Acute graft-versus-host disease; JAK inhibitors; allogeneic hematopoietic cell transplantation; corticosteroids; extracorporeal photopheresis; fecal microbiota transplantation; mesenchymal stromal cells; ruxolitinib
    DOI:  https://doi.org/10.1080/17474086.2026.2760637
  53. Curr Top Med Chem. 2026 Oct 28.
      Chimeric Antigen Receptor (CAR)-engineered immune cells now extend well beyond autologous CAR-T therapy to span early-clinical NK, invariant natural killer T, gamma-delta T, and double-negative T platforms, clinical-stage regulatory T-cell programs, preclinical macrophage, neutrophil and dendritic-cell systems, and adjacent BCR/antibody-engineered B-cell approaches. This Perspective proposes a chassis-aware framework in which target biology and tissue location determine the required effector function, and this function in turn constrains cell source, receptor architecture and antigen logic, engineering route, developability assays, and safety controls, rather than allowing receptor design to be transferred unchanged from the CD19 CAR-T precedent. Each chassis requires a lineage-adapted signalling architecture, and ex vivo and in vivo programming are treated as distinct pharmacological strategies with different implications for expression duration, biodistribution, off-target transduction, redosing, and rescue. Clinical translation further requires chassis- and route-specific potency assays, predefined critical quality attributes, batch comparability, quantitative biodistribution and persistence measurements, and controls for lineage instability or suppressive polarization. Treating each chassis-route combination as a distinct therapeutic hypothesis, rather than a variant of CAR-T, provides a testable and generalizable route from molecular design to clinical and regulatory development.
    Keywords:  CAR-NK; CAR-T; CAR-dendritic cell; CAR-macrophage; CAR-neutrophil; Chimeric antigen receptor; engineered B cell; in vivo engineering; living therapeutics
    DOI:  https://doi.org/10.2174/0115680266534378261027112811
  54. J Cancer Policy. 2026 Nov 06. pii: S2213-5383(26)00131-1. [Epub ahead of print] 100830
       BACKGROUND: The approval of oncology therapies has increasingly incorporated biomarker-driven precision medicine. However, the influence of mandatory biomarker selection on regulatory pathways remains poorly understood. We compared the regulatory characteristics of targeted and non-targeted oncology therapies first authorised in the European Union between 2015 and 2025.
    METHODS: We conducted a retrospective analysis of drug-indication pairs for solid tumours first authorised following EMA assessment and European Commission marketing authorisation between January 2015 and December 2025. Therapies were classified as targeted when mandatory biomarker testing was required for patient selection in the approved indication. Regulatory characteristics and timelines were obtained from publicly available EMA information. The primary regulatory outcome was Conditional Marketing Authorisation (CMA).
    RESULTS: Eighty-one drug-indication pairs were included: 43 targeted (53.1%) and 38 non-targeted (46.9%). No significant linear temporal trend in the proportion of targeted therapies was detected (OR per year 1.12; 95% CI 0.97-1.28; p=0.113). CMA was granted to 44.2% of targeted versus 7.9% of non-targeted therapies (OR 9.24; 95% CI 2.46-34.71; p<0.001). The association remained directionally consistent across sensitivity analyses accounting for calendar year, pharmacological class, tumour type, and multiple indications within the same application. No significant difference in total elapsed time to marketing authorisation was detected (median 419 vs 443 days; median difference -24 days; 95% bootstrap CI -74 to 10).
    CONCLUSIONS: Targeted oncology therapies requiring mandatory biomarker selection were substantially more likely than non-targeted therapies to receive CMA, although the magnitude of the association was imprecisely estimated.
    POLICY SUMMARY: Greater use of CMA among targeted therapies means that more indications enter the post-authorisation period with confirmatory evidence obligations outstanding. This may be relevant to HTA and reimbursement decisions and warrants longitudinal research on how these obligations and the evidence base evolve after authorisation.
    Keywords:  Biomarker-Driven Therapy; Conditional Marketing Authorisation; European Medicines Agency; Health Technology Assessment; Precision Medicine; Regulatory Pathways
    DOI:  https://doi.org/10.1016/j.jcpo.2026.100830
  55. Clin Transl Sci. 2026 Nov;pii: e70768. [Epub ahead of print]19(11):
      Antibody-drug conjugates (ADCs) are among the most pharmacologically complex therapeutics in clinical development. Their behavior emerges from the interplay of antibody disposition, linker stability, payload pharmacology, and host physiology-interdependencies that render qualitative descriptors such as "stronger affinity" or "more potent payload" insufficient for reliable prediction of preclinical and clinical outcomes. Despite growing investment in quantitative medicine across drug development, no unified framework exists to guide quantitative decision-making across the ADC design-development-dose-optimization continuum. In this review we survey how fit-for-purpose quantitative approaches inform decisions at each stage of the development path, built on multi-analyte data pipelines that capture the coupled pharmacokinetics (PK) of antibody, linker-payload, and released payload. We highlight the utility of PBPK-driven (physiologically-based pharmacokinetics) feasibility and mechanistic sensitivity analyses for candidate triage and allometric and mechanism-based translation for human exposure predictions. We also present a stepwise construction of exposure-response relationships bridging preclinical and clinical data and integration of efficacy and safety into a clinical utility index for dose optimization. Throughout, we argue that the central challenge for quantitative ADC development is not the absence of sophisticated models, but the disciplined integration of fit-for-purpose approaches into the decisions that shape the development path. We synthesize these ideas in the proposition of a preclinical clinical utility index (pCUI) as an efficacious lens for model-informed ADC development: an integrative benefit-risk framework expanding on the established clinical utility index (CUI) that quantitatively assesses whether a therapeutic window plausibly exists before first-in-human dosing.
    DOI:  https://doi.org/10.1111/cts.70768
  56. Eur J Cancer. 2026 Nov 03. pii: S0959-8049(26)01602-3. [Epub ahead of print]249 117820
       BACKGROUND: Chimeric antigen receptor (CAR) T-cell therapy has been compared with established non-CAR T treatments in several hematological malignancies, but the magnitude and consistency of benefit across diseases and comparators remain unclear. We conducted a systematic review and meta-analysis of comparative studies in non-Hodgkin lymphoma (NHL), acute lymphoblastic leukemia (ALL), and multiple myeloma (MM).
    METHODS: 71 comparative studies evaluating CAR T-cell therapy versus standard chemoimmunotherapy (SOC), targeted therapy (TAT), transplantation, chemotherapy or donor lymphocyte infusion (DLI) comparators were included. Outcomes were analyzed separately by disease entity. Treatment effects were summarized using odds ratios (ORs) for response and hazard ratios (HRs) for survival with random-effects models.
    RESULTS: In NHL, largely driven by large B-cell lymphoma (LBCL), CAR T-cell therapy increased response compared with SOC (OR=2.48, 95% CI=1.35-4.57) and improved overall survival (OS) (HR=0.61, 95% CI=0.48-0.78). Progression-free survival (PFS) was longer with CAR T-cells therapy than SOC in second-line LBCL, whereas no clinical advantage was observed over TAT or transplantation. In follicular lymphoma, CAR T-cells prolonged PFS versus SOC, while OS differences varied across comparators. In MM, CAR T-cells increased PFS compared with SOC or TAT (HR=0.30, 95% CI=0.11-0.77) and OS favored CAR T-cell infused patients. In ALL, OS favored CAR T-cell versus chemotherapy or DLI (HR 0.30, 95% CI=0.25-0.36) and was associated with fewer graft-versus-host disease events after transplantation.
    CONCLUSIONS: CAR T-cell therapy provides disease- and comparator-specific efficacy advantages without increased overall toxicity. Benefits are most consistent for PFS in LBCL and MM, however, in ALL, further comparator-specific evidence is needed.
    Keywords:  Acute lymphoblastic leukemia; Adverse events; Chimeric antigen receptor T-cell therapy; Complete response; Multiple myeloma; Non-Hodgkin lymphoma; Overall survival
    DOI:  https://doi.org/10.1016/j.ejca.2026.117820
  57. Cell Mol Immunol. 2026 Nov 04.
      The clinical success of T-cell-based immunotherapies has transformed oncology, yet tumor immune evasion remains a formidable barrier. In this review, we delineate the developmental and molecular landscapes that shape antitumor T-cell immunity. Following a brief overview of CD4+ helper T-cell contributions, we focus primarily on CD8+ cytotoxic lineages. Rather than a passive loss of effector function, CD8+ T-cell exhaustion is increasingly recognized as functional attrition and profound oligoclonality. In the immunosuppressive tumor microenvironment (TME), unremitting antigenic pressure drives an iterative selection process that` narrows a highly diverse T-cell pool into a constricted, oligoclonal population, a phenomenon termed "clonal contraction". We expand the conceptual scale of T-cell clonal selection during the immune response, tracing this clonal evolution from early thymic selection and primary antigen priming to exhaustive terminal differentiation. We further propose a structural model demonstrating how the biophysical constraints of a fixed T-cell receptor (TCR) repertoire create a profound imbalance against rapidly diversifying tumor antigens. Within this framework, we highlight tissue-resident memory (Trm) as a crucial spatial reservoir that safeguards the host against the depletion of functional clones. Finally, we contextualize the therapeutic paradigm of immune checkpoint inhibition (ICI) and note that, under some circumstances, durable clinical efficacy can be driven by systemic "clonal replacement". Ultimately, we argue that next-generation T-cell-based immunotherapies may shift `from attempting only to reverse functional exhaustion to actively engineering continuous clonal selection and preserving TCR repertoire diversity.
    Keywords:  Checkpoint inhibitors; Clone evolution; Immunotherapy; T cells; TCR diversity
    DOI:  https://doi.org/10.1038/s41423-026-01483-y
  58. Blood. 2026 Nov 05. pii: blood.2026034987. [Epub ahead of print]
      No chimeric antigen receptor therapy (CAR-T) is currently approved for WM. This study assessed safety and efficacy of CD20-targeted CAR-T in BTKi-refractory, heavily pre-treated WM patients. With a CR/VGPR rate of 80%, this treatment should be evaluated in larger trials. ClinicalTrials.gov number NCT03277729.
    DOI:  https://doi.org/10.1182/blood.2026034987
  59. ASM Case Rep. 2026 Nov;pii: e00047-26. [Epub ahead of print]2(6):
       Background: Campylobacter jejuni is a leading cause of bacterial gastroenteritis worldwide and typically results in self-limiting enterocolitis in immunocompetent individuals. In contrast, immunocompromised patients are at risk for severe, recurrent, or persistent infection. Chimeric antigen receptor (CAR) T-cell therapy targeting CD19 induces prolonged B-cell aplasia and hypogammaglobulinemia, predisposing patients to atypical infections. We report the first case of persistent and disseminated C. jejuni infection following CD19-directed CAR T-cell therapy, confirmed by whole-genome sequencing.
    Case Summary: A 68-year-old man with relapsed follicular lymphoma underwent autologous CD19-directed CAR T-cell therapy and achieved complete remission. Pre-existing hypogammaglobulinemia worsened after treatment. Eighteen months later, he developed recurrent bacteremia and chronic enterocolitis caused by C. jejuni. Over the following year, he experienced severe watery diarrhea, 20 kg weight loss, and disseminated infection with a prosthetic hip abscess. More than 10 stool cultures remained positive despite multiple antibiotic regimens and two fecal microbiota transplantations. Whole-genome sequencing demonstrated a single clonal strain with minimal variation, confirming persistent infection rather than reinfection. Microbiological clearance was achieved after 8 weeks of oral gentamicin, followed by 2 weeks of intravenous meropenem and azithromycin, with sustained negative cultures and PCR.
    Conclusion: Persistent and disseminated C. jejuni infection can occur in patients with hypogammaglobulinemia after CD19-directed CAR T-cell therapy. Whole-genome sequencing may help distinguish persistence from reinfection. Standard immunoglobulin replacement may be insufficient due to limited IgA and IgM, and prolonged combination antimicrobial therapy may be required for durable remission.
    Keywords:  CAR T-cell therapy; Campylobacter jejuni; hypogammaglobulinemia; persistent infection
    DOI:  https://doi.org/10.1128/asmcr.00047-26
  60. Ann Biomed Eng. 2026 Nov 06.
      Many foundation models that have entered medicine are language models, although foundation models for imaging and other modalities have also emerged. A second class is now emerging from robotics and autonomous driving, trained not to produce text but to predict how an environment evolves under action, and marketed under the designation world foundation model. We argue that medicine should approach this class with a specific form of caution. Medicine already possesses world models in the mechanistic simulators and digital twins built from physiology and physics, and the constraint on those has never been the volume of available data. The constraint is identifiability. A simulator learned from observational clinical records inherits the treatment policies that generated them, and rolling such a model forward under an alternative treatment recovers the practice pattern rather than the underlying physiology. We distinguish the settings where learned world models are likely to succeed from those where they will reproduce confounding at scale, and set out what validation would require.
    Keywords:  Confounding by indication; Generative AI; Generative video synthesis; Physical artificial intelligence; Physiological modelling; Reinforcement learning; Surgical robotics
    DOI:  https://doi.org/10.1007/s10439-026-04445-7